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and a review of the literature. They highlight the need to act 
early to prevent CKD and other related noncommunicable 
diseases later in life by reducing low birth weight, small for 
gestational age, prematurity, and low nephron numbers at 
birth through coordinated interventions. Meeting the cur-
rent unmet needs would help to define the most cost-effec-
tive strategies and to optimize interventions to limit or inter-
rupt the developmental programming cycle of CKD later in 
life, especially in the poorest part of the world. 
 © 2017 The Author(s)
Published by S. Karger AG, Basel 
 Preface 
 This consensus document aims to address the rela-
tively neglected issue of the developmental program-
ming of hypertension and chronic kidney disease (CKD). 
It emerged from a workshop, entitled The Fault Is Not 
in Our Stars but May Be in Our Embryos – Glomerular 
Number in Low Birth Weight Babies, held at the Clinical 
Research Center for Rare Diseases Aldo e Cele Daccò, 
IRCCS – Mario Negri Institute for Pharmacological Re-
search, Bergamo, Italy, on April 2, 2016, including emi-
nent internationally recognized experts in the field of 
 Keywords 
Low birth weight · Nephron number · Intrauterine growth 
restriction · Small for gestational age · Preterm birth · 
Programmed risk of hypertension · Programmed risk 
of kidney disease · Maternal nutrition · Infant and child 
nutrition · Neonatal acute kidney injury
 Abstract 
Hypertension and chronic kidney disease (CKD) have a sig-
nificant impact on global morbidity and mortality. The Low 
Birth Weight and Nephron Number Working Group has pre-
pared a consensus document aimed to address the relative-
ly neglected issue for the developmental programming of 
hypertension and CKD. It emerged from a workshop held on 
April 2, 2016, including eminent internationally recognized 
experts in the field of obstetrics, neonatology, and nephrol-
ogy. Through multidisciplinary engagement, the goal of the 
workshop was to highlight the association between fetal 
and childhood development and an increased risk of adult 
diseases, focusing on hypertension and CKD, and to suggest 
possible practical solutions for the future. The recommenda-
tions for action of the consensus workshop are the results of 
combined clinical experience, shared research expertise, 
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obstetrics, neonatology, and nephrology (see Appen-
dix). The goal of the workshop through multidisci-
plinary engagement was to highlight the association be-
tween fetal and childhood development and an increased 
risk of adult diseases, focusing on hypertension and 
CKD, and to suggest possible practical solutions for the 
future. Low birth weight (LBW), growth restriction, and 
preterm birth are the most consistent clinical surrogates 
for low nephron numbers and are associated with an in-
creased risk of hypertension, proteinuria, and kidney 
disease later in life. This relationship is amplified by the 
development of acute kidney injury (AKI) in preterm 
infants, which may further reduce nephron numbers 
soon after birth, as well as by rapid catch-up growth or 
overfeeding during infancy or childhood in children 
born small, which may further augment the risk of hy-
pertension and CKD and predispose to obesity and type 
2 diabetes later in life. Many questions about the devel-
opmental origins of chronic renal disease, possible nu-
tritional and pharmacologic interventions, as well as 
strategies for optimal follow-up and management of 
vascular, metabolic, and renal functions remain unan-
swered. The working group has discussed in depth how 
to raise awareness about developmental programming 
and renal disease risk later in life, and practical, locally 
adaptable preemptive strategies were suggested that 
could have long-term benefits in terms of future kidney 
health and cost saving worldwide. The discussion ended 
with the consensus recommendations presented here. 
This document is well aligned with the recent emphasis 
on a “life course” approach outlined by the World Health 
Organization (WHO) in the Minsk Declaration and the 
Global Action Plan for the Prevention and Control of 
Noncommunicable Diseases (NCD)  [1, 2] . In both doc-
uments, the need to begin to prevent later-life chronic 
disease even before conception is emphasized, but spe-
cific recommendations beyond general nutritional in-
terventions have not yet been made  [3] . In turn, the life 
course approach aligns with the targets proposed by the 
United Nations 2030 Agenda for Sustainable Develop-
ment, where a much broader approach is advocated to 
maintain health, and many goals are highly relevant to 
renal development and kidney disease  [4] .
 Introduction to a Health Problem 
 The Global Burden of NCD 
 The WHO endorsed the Global NCD Action Plan in 
2008 in response to growing recognition that NCD have 
replaced communicable diseases as the predominant 
causes of premature mortality worldwide  [2] . Neverthe-
less, the global burden of NCD has been relatively ne-
glected by policy makers, major aid donors, and academ-
ics until recently, given the global push to address com-
municable diseases over the past decade which diverted 
funds from NCD  [5] . The NCD Action Plan aims to re-
duce premature mortality from cardiovascular disease 
(CVD), diabetes, cancer, and chronic lung disease by 25% 
by 2020 and emphasizes prevention as a crucial strategy 
to reduce NCD  [2] . A “life course approach” is suggested 
as 1 of 9 overarching approaches for the prevention of 
NCD and has been highlighted in the recent Minsk Dec-
laration, reflecting the increasing realization that early 
development is a determinant of later-life health and dis-
ease  [1, 2] . Optimizing early development provides the 
chance for true primary prevention of NCD with major 
potential multiplier effects on overall health and well-
being throughout life  [4] .
 The worldwide prevalence of chronic diseases is pro-
jected to increase substantially over the next few decades 
 [6] . For example, according to the International Diabetes 
Federation, the worldwide prevalence of diabetes is pre-
dicted to rise from 415 to 642 million between 2015 and 
2040  [7] . In addition, by 2025, more than 75% of the 
world’s diabetic population will reside in low- and mid-
dle-income countries (LMIC)  [8] . Similarly, the preva-
lence of ischemic heart disease has almost doubled glob-
ally between 1990 and 2013  [9] . Although age-standard-
ized mortality rates attributed to NCD have fallen 
worldwide, NCD remain the leading cause of death in the 
world, as shown by the 42% increase in the number of 
NCD-related deaths from 27 to 39.8 million between 
1990 and 2015  [10] . Thus, the social, economic, and pub-
lic health consequences of the expected increase in most 
NCD could have devastating consequences especially for 
LMIC.
 CKD: A Global Health Problem 
 CKD is a key determinant of poor health outcomes for 
major NCD and has a risk-multiplier effect on CVD  [11] . 
Recent findings from the Global Burden of Disease Study 
have highlighted CKD as an important cause of global 
mortality  [10] . The number of reported deaths due to 
CKD was estimated to be 1.2 million, a 32% increase from 
2005, with deaths from diabetic and hypertensive kidney 
disease comprising over 75% of these deaths  [10] . The 
prevalence of end-stage kidney disease (ESKD) patients 
receiving renal replacement therapy (RRT) with mainte-
nance dialysis has increased 1.7 times from 165 patients 
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per million population in 1990 to 284 patients per million 
population worldwide in 2010  [12] . The number of peo-
ple who will receive RRT (dialysis or transplantation) 
worldwide has been projected to more than double from 
2.6 to 5.4 million from 2010 to 2030  [13] . Notably, it has 
been estimated that between 2.3 and 7.1 million people 
who could have been kept alive with RRT in 2010 died 
prematurely because they did not have access to the treat-
ment  [13] . Most of these deaths occurred in Asia, Africa, 
and Latin America, where RRT remains unaffordable 
 [11] . With a population that is aging, steep increases in 
the worldwide incidence of type 2 diabetes mellitus and 
hypertension are driving the growth in the CKD burden, 
putting an enormous pressure on health care resources 
 [11] . ESKD is only the tip of the iceberg. CKD occurs in 
approximately 10% of the population  [11] . While the true 
prevalence of CKD in many LMIC countries remains ill 
defined  [14] , in industrialized countries CKD affects 
more disadvantaged populations and ethnic minorities 
and, therefore, causes a disproportionate burden on the 
poor  [11] . Kidney disease is, therefore, a global public 
health priority. Given the very high individual and soci-
etal costs of treatment, prevention is the most effective 
strategy to sustainably address the growing global burden 
of kidney disease.
 Developmental Programming of Chronic Diseases 
 The large individual variability in susceptibility to kid-
ney disease and other NCD remains unexplained. Genet-
ic predisposition and environmental exposures are con-
tributory factors, but increasingly it is being recognized 
that fetal development is also an important modulator of 
the NCD risk. The quality and quantity of nutrition re-
ceived during fetal life, exposure to pollutants, drugs, and 
infections during gestation, as well as the mother’s health 
while she is pregnant, all impact fetal kidney development 
 [15] . Perinatal exposures and nutrition as well as early 
childhood growth are also important. Since the first ob-
servations that adults who were born with LBW (defined 
as a birth weight <2.5 kg) were at a higher risk of prema-
ture cardiovascular death, increasingly compelling epide-
miologic and experimental evidence has highlighted the 
“programming” impact of intrauterine and early child-
hood stresses on organ development and long-term or-
gan functions  [16, 17] . LBW, growth restriction, and pre-
term birth (defined in  Table 1 ) have been the most acces-
sible surrogate markers for intrauterine stress so far.
 Although programming associations between LBW, 
growth restriction, preterm birth, and hypertension have 
been studied the most, evidence pointing to associations 
between LBW and CKD, CVD, obesity, glucose intoler-
ance, type 2 diabetes, and preeclampsia is also quite con-
 Table 1.  Definitions of birth weight categories and preterm birth
Category Definition
Birth weight categories
Normal birth weight >2,500 and <4,000 g (usually)
Large for gestational age >2 SD above the mean birth weight for gestational age
Low birth weight <2,500 g
Very low birth weight <1,500 g
Appropriate for gestational age ±2 SD of the mean birth weight for gestational age
Small for gestational age >2 SD below the mean birth weight for gestational age
Intrauterine growth restriction Evidence of fetal malnutrition and growth restriction at any time during 
gestation
Gestational categories
Extremely preterm <28 weeks’ gestation
Very preterm <32 and >28 weeks’ gestation
Moderately preterm <34 and >32 weeks’ gestation
Late preterm <37 and >34 weeks’ gestation
Full term >37 weeks’ gestation
 Term fetal macrosomia implies fetal growth beyond a specific weight, usually 4.0 or 4.5 kg, regardless of fetal 
gestational age [18, 19]. In this document, we use the term “growth restriction” to refer to both SGA and IUGR 
[reprinted with permission from 20].
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vincing  [16, 17, 21–25] . Until recently, research has 
largely focused on LBW and preterm birth as markers for 
developmental programming of hypertension and renal 
disease, but high birth weight (HBW), often as a result of 
a diabetic pregnancy or maternal obesity, is also emerg-
ing as a risk factor  [18, 26, 27] . It is important to recog-
nize that many babies who are born yearly with birth 
weights above 2.5 kg (technically not LBW) still expe-
rienced intrauterine growth restriction (IUGR) and
may be inappropriately small for gestational age (SGA) 
( Fig. 1 ).
 In addition, preterm infants may also have either an 
appropriate, although low, birth weight for gestational 
age (AGA) or may be SGA if they experienced superim-
posed growth restriction ( Fig. 1 ). Such growth restriction 
per se  is also associated with programming effects in the 
kidney, emphasizing the continuum of the programming 
risk and the need for heightened awareness of this risk 
 [29–32] . Worldwide, the incidence rates of LBW and pre-
term birth lie at around 15–20% and 11%, respectively 
 [33, 34] . There is, however, significant overlap between 
LBW, preterm birth, and SGA, with the total reaching 
around 36% of live births in LMIC in 2010  [28] . Globally, 
the incidence of HBW is increasing, ranging from 5 to 
20%, with many infants probably exposed to maternal di-
abetes or obesity  [18] . Therefore, many infants born every 
year likely undergo developmental programming, which 
may be the first in a succession of “hits” that ultimately 
manifest in overt disease. Consequently, the population 
impact of developmental programming may be consider-
able. For example, a population-based study in the US 
found that of every 13 adolescents born with LBW, or 5 
with very low birth weight (VLBW), 1 had elevated sys-
tolic blood pressure and 1 had a reduced glomerular fil-
tration rate (GFR)  [35] . These numbers would be expect-
ed to increase as subjects age.
 Fig. 1. Number of infants born small for gestational age (SGA) or with low birth weight (LBW), and premature 
birth in low- and middle-income countries – 2010 (reprinted with permission according to CC Creative Com-
mons Attribution-NonCommercial-noDerivs from Lee et al.  [28] ). A large number of infants born at term and 
SGA do not meet the definition of LBW and, therefore, likely experienced programming but may not be identi-
fied as at risk. 
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 The Low Nephron Number Hypothesis 
 Under normal developmental conditions, nephrogen-
esis continues until the 36th week of gestation in utero, 
and no new nephrons develop following birth in full-term 
infants  [36] .
 Building on early epidemiologic evidence linking LBW 
and adult CVD, Brenner et al.  [37] hypothesized that de-
velopmental programming in the kidney may result in a 
reduction in nephron number, which in turn may be a fac-
tor contributing to higher blood pressure and increased 
risk of CKD. The authors hypothesized that a reduction in 
whole kidney glomerular surface area resulting from a pro-
grammed reduction in nephron number would enhance 
susceptibility to hypertension by limiting sodium (salt) ex-
cretory capacity and increase susceptibility to CKD through 
a reduced capacity to compensate for renal injury. Consis-
tent with this possibility, LBW, hypertension, and CKD, all 
tend to occur more frequently in poorer populations  [38–
42] . In animal studies early on, feeding pregnant rats a low-
protein diet induced LBW in the offspring, which sub-
sequently developed spontaneous hypertension that in-
creased with age, chronic renal injury, and premature 
death  [43–45] . The rat offspring also had smaller kidneys 
and reduced nephron numbers, which strongly supports 
the nephron number hypothesis. Although the magnitude 
of programming effects observed often differs between 
males and females  [46] and between experimental condi-
tions, many diverse animal studies also strongly support 
the association between adverse intrauterine conditions 
and a higher risk of hypertension and renal dysfunction 
with age, as reviewed elsewhere  [47, 48] .
 Nephron Numbers in Humans 
 The inability to determine nephron number in living 
humans has been a major obstacle to definitively inves-
tigating the nephron number hypothesis. To date, all 
nephron-counting studies have been performed on au-
topsy samples. From 7 studies with nearly 500 subjects, 
we know that the average nephron number is  ∼ 1,000,000 
per kidney  [49–54] . Human nephron number is highly 
variable, however, ranging from 210,000 to1 2.7 million 
 [53] . This 13-fold variability likely contributes to indi-
vidual susceptibility to hypertension and kidney disease 
 [51, 52, 55] . Significant variability is already present at 
birth, highlighting the importance of early nephrogene-
sis  [56, 57] . Nearly 60% of nephrons are developed in the 
third trimester of pregnancy  [58] . In preterm infants, 
nephrogenesis may occur for up to 40 days after birth, 
but may be abnormal  [57, 58] . Nephron numbers have 
been found to be reduced in infants who were born pre-
term or of LBW  [58–61] . Importantly, however, it has 
been observed in some animal models that low nephron 
numbers may also occur with normal birth weight, so the 
burden or risk of renal programming may be underesti-
mated if birth weight is the only surrogate marker con-
sidered  [62] . Over time, nephron numbers decline due to 
age-related glomerulosclerosis and obsolescence, and 
thus age is also an important risk modifier of the pro-
grammed renal risk  [51, 63, 64] . Further clinical surro-
gates associated with reduced nephron numbers in hu-
mans include adult height, female gender, Australian 
Aboriginal ethnicity, and maternal vitamin A deficiency 
 [65, 66] ( Table 2 ).
 Table 2.  Clinical associations with low nephron numbers [reproduced with permission from 67]
Clinical feature Association with nephron number Population Reference
Low birth weight ↑ of 257,426 glomeruli per kilogram 
increase in birth weight
USA white and black, children and adults 60
Prematurity ↓ glomerular number in preterm vs. term 
infants
US premature and full-term neonates 58, 59
Gender Nephron number is 12% lower in females USA white and black, Aboriginal Australian 66
Age ↓ 3,676 glomeruli per kidney per year of age 
>18 years
USA white and black, Aboriginal Australian 66
Adult height ↑ 28,000 glomeruli per centimeter increase in 
height
Aboriginal Australian, German, white 52, 66
Kidney mass ↑ 23,459 glomeruli per gram of kidney 
tissue
Infants <3 months of age 68
Glomerular volume Inverse correlation between glomerular volume 
and nephron number
US white and black, Aboriginal Australian, 
German adults, Cuban infants
52, 55, 61
Ethnicity ↓ Aboriginal Australian vs. US white and black US white and black, Aboriginal Australian 66
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 Nephron numbers have been shown to correlate with 
kidney weight, so renal mass has also been used as a sur-
rogate marker for nephron numbers, although this rela-
tionship may be confounded by renal hypertrophy  [51, 
68, 69] . In all studies, glomerular numbers correlate in-
versely with glomerular volume, largely independent of 
gender and race, potentially reflecting compensatory glo-
merular hyperfiltration  [55, 61, 70] . Therefore, glomeru-
lar volume has also been proposed as a surrogate marker 
for reduced nephron numbers in the absence of other 
causes. A promising innovative method for nephron enu-
meration is the use of cationic ferritin as an MRI-detect-
able contrast agent, which highlights the glomerular base-
ment membrane of each nephron  [71–74] . This contrast 
allows for the quantification of all glomeruli in a nonde-
structive manner and may potentially be useful in vivo. A 
more definitive quantification of nephron numbers in 
real time would permit more comprehensive and larger-
scale studies of the relationship between nephron num-
ber, clinical parameters, and the risk of hypertension and 
renal disease.
 Nephron numbers increase in proportion to birth 
weight and gestational age  [60] . Importantly, there is no 
known discrete threshold above which a nephron num-
ber is “high enough”; nephron numbers occur along a 
continuum in the population, as does disease risk. It is 
likely, however, that individuals with nephron numbers 
on the lower side of the spectrum are those at higher risk 
of hypertension and kidney disease  [52] . The relationship 
between an individual’s body size (metabolic demand) 
and nephron numbers is probably an important modula-
tor of this risk  [75] . Superimposed renal “hits” or other 
risk modifiers, therefore, likely determine the phenotypic 
expression of disease along the spectrum of nephron 
number. It is clear that better biomarkers for the early de-
tection of renal structural changes are needed to help pre-
dict which LBW, SGA, or preterm infant will develop
hypertension and CKD. 
 Developmental Programming of Hypertension and 
Kidney Disease 
 Programmed Associations with Blood Pressure 
 LBW and preterm birth are both associated with an 
increased risk of elevated blood pressure in later life. Me-
ta-analyses have shown that systolic blood pressure levels 
were higher in preterm or VLBW adolescents than in 
controls born at term (mean increase of 2.5 mm Hg; 95% 
confidence interval, CI, 1.7–3.3 mm Hg from 10 studies) 
and in subjects with birth weights <2.5 kg compared with 
 ≥ 2.5 kg (mean increase 2.28 mm Hg; 95% CI, 1.24–3.33 
from 9 studies). In the latter study, the odds ratio (OR) of 
overt hypertension was 1.21 (95% CI, 1.13–1.3) for those 
with birth weights <2.5 kg compared with  ≥ 2.5 kg  [22] . A 
systematic review of the impact of HBW on blood pres-
sure, however, also found a risk ratio of 1.18 (95% CI, 
1.05–1.32 from 6 studies) for hypertension in children 
who had birth weights  ≥ 4 kg compared with birth weights 
<4 kg, but this effect did not persist in adults  [27] . In a 
further meta-analysis of 13 studies including 1,115 chil-
dren aged 2–20 years exposed to diabetes during gesta-
tion, systolic blood pressure levels were found to be high-
er compared to controls (mean difference 1.88 mm Hg; 
95% CI, 0.47–3.28); however, this effect appeared to pre-
dominate in males  [76] . Similarly, a systematic review 
found that systolic blood pressure levels were 2.39 mm 
Hg (95% CI, 1.74–3.05 from 18 studies) higher among 
young adults who had been exposed to preeclampsia  [77] . 
Longer-term studies are required to determine the impact 
of preterm birth, exposure to diabetes, and preeclampsia 
on blood pressure in older cohorts.
 Number of Nephrons in Human Subjects with 
Primary Hypertension 
 In white adults aged 35–59 years who died in acci-
dents, nephron numbers were significantly reduced in 10 
subjects with known essential hypertension compared 
with 10 matched normotensive controls  [52] . Although 
birth weights were unknown, this study supports an as-
sociation between reduced nephron numbers and the risk 
of essential hypertension. In other studies, nephron num-
bers were found to be lower in Caucasians, or Aboriginal 
Australians, with higher blood pressure levels  [52, 66, 78] . 
This relationship was not as strong in African-Ameri-
cans, although hypertension was more prevalent in those 
with nephron numbers below the group mean, implying 
that nephron numbers likely have a modifying effect on 
hypertension in this population  [78] . Hypertension in-
creases with glomerular volume in both white and Afri-
can-American subjects, although the probability of devel-
oping hypertension is universally higher for African-
American subjects  [55] . A better understanding of the 
ethnic variability in developmental programming risks is 
important to refine our understanding of the pathophys-
iology of the programming of hypertension. The findings 
that salt sensitivity of blood pressure in humans is associ-
ated with LBW and a small kidney size are consistent with 
altered sodium handling having a role in the pathogenesis 
of hypertension in LBW subjects, which may at least par-
tially be mediated by a reduction in nephron numbers 
 [79–81] .
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 Other Programmed Factors Contributing to 
Increased Blood Pressure 
 Low nephron numbers alone are not always associated 
with programmed hypertension, suggesting that addi-
tional factors also contribute to this phenotype. Restoring 
nephron numbers by supplementing a low-protein diet 
with urea or alanine in pregnant rats did not prevent the 
programmed rise in blood pressure of the rat offspring, 
whereas supplementation with glycine did, suggesting 
that varying amino-acid deficiencies during gestation 
may have different programming effects on the kidney 
 [82] . Similarly, postnatal hypernutrition in normal rats 
led to obesity, hypertension, and glomerulosclerosis with 
age, despite a 20% increase in nephron numbers  [83] . 
Other elegant studies have demonstrated changes in renal 
tubular sodium handling in all tubule segments and al-
tered vascular function in developmentally programmed 
animals that likely also contribute to blood pressure and 
renal function changes later in life  [84, 85] . As with neph-
ron number studies, the varying experimental conditions 
and animals used are associated with variations in the 
programmed phenotype, which underscores the likely 
multifactorial nature and ramifications of developmental 
“hits.”
 Clinical Associations of Renal Programming with 
Renal Function and CKD 
 LBW has been the best-studied marker for having ex-
perienced an adverse intrauterine environment and renal 
developmental programming  [15] . Studies have shown 
strong associations with fewer and bigger glomeruli, a 
greater risk of hypertension, proteinuria, salt sensitivity 
of blood pressure, and progressive CKD  [16, 22, 60, 61, 
65, 78–80, 86] . Overall, a meta-analysis of 31 studies, in-
cluding over 2 million subjects, documented that in LBW 
offspring the risk of developing CKD (defined as albu-
minuria, a reduced GFR, or renal failure) in later life is 
increased by 70%  [16] . In a Norwegian population-based 
study, the odds of a reduced GFR (<100 mL/min) were 
1.66 (95% CI, 1.16–2.37) in men and 1.65 (95% CI, 1.17–
2.35) in women who were born SGA compared with 
AGA, which increased further among those who had 
been very small for gestational age, demonstrating a dose-
response effect  [32] . Studies examining renal function af-
ter preterm birth have thus far been conducted predomi-
nantly in children, and many have described an associa-
tion with reduced GFR and increased urinary albumin 
excretion among those who had been born preterm  [30, 
31, 87–89] . In a cohort of young adults born preterm, 
birth weight correlated negatively with microalbumin-
uria and positively with GFR  [90] . In addition, those who 
had been preterm and SGA had a 2.4-fold (95% CI, 0.6–
9.3) increase in microalbuminuria, suggesting an addi-
tional impact of growth restriction. Although changes in 
renal function are generally small and may still be within 
the normal range in children and adolescents, these may 
progress to overt renal dysfunction with age or superim-
posed renal insults. Potentially consistent with this hy-
pothesis is a population-based case-control study in sub-
jects with known childhood CKD (<21 years of age); LBW 
was significantly associated with an increased risk of CKD 
(OR 2.88; 95% CI, 2.28–3.63), renal dysplasia/aplasia (OR 
4.51; 95% CI, 3.47–5.85), and a reduced GFR (OR 6.36; 
95% CI, 4.00–10.12) [91] ( Table 3 ).
 Exposure to maternal diabetes and overweight/obesity 
are also increasingly being recognized as risk factors for 
renal developmental programming. It has long been 
known that exposure to diabetes during gestation leads to 
 Table 3.  Prenatal risk factors for childhood CKD [adapted from 91]
Neonatal factors  Maternal factors
LBW HBW  preexisting DM GDM overweight obesity
Crude OR 
95% CI
2.41 
2.08 – 2.80
1.17 
1.03 – 1.34
1.97 
1.15 – 3.37
1.40 
1.11 – 1.77
1.19 
1.02 – 1.38
1.27 
1.08 – 1.49
Adjusted OR1 
95% CI
2.88 
2.28 – 3.63
0.97 
0.79 – 1.21
1.12 
0.4 – 2.84
1.54 
1.13 – 2.09
1.24 
1.05 – 1.48
1.26 
1.05 – 1.52
 CI, confidence interval; DM, diabetes mellitus; HBW, high birth weight; OR, odds ratio. Chronic kidney dis-
ease (CKD) defined by ICD-9 code 585.x, including obstruction and dysplasia. 
1 Adjustments listed in primary reference included maternal body mass index, smoking, and gestational hy-
pertension.
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congenital malformations of the kidney, and the risk 
seems to persist after controlling for maternal body mass 
index (BMI)  [91] . Diabetes during pregnancy is associ-
ated with HBW, which in turn has been associated with 
increased risks of proteinuria and ESKD  [26, 39] . It has 
been suggested that exposure to diabetes during gesta-
tion, rather than genetic factors, is a mediator of renal 
programming in offspring based on the finding that renal 
functional reserve is lower in young adult offspring of 
mothers with diabetes during gestation than in those with 
diabetic fathers  [92] . In animals, maternal diabetes expo-
sure (models of type 1 and 2 diabetes) is associated with 
reduced nephron numbers in offspring, which would be 
consistent with a reduction in renal functional reserve 
 [93, 94] .
 As shown in  Table 3 , the adjusted OR for childhood 
CKD following exposure to maternal diabetes was in-
creased in unadjusted analyses but was attenuated in 
those with pregestational diabetes after adjustment for 
maternal BMI and smoking  [91] . Exposure to maternal 
overweight and obesity was also independently associat-
ed with increased odds of childhood CKD  [91] . The OR 
for renal dysplasia or aplasia was significantly increased 
with maternal pregestational type 1 or 2 diabetes, where-
as gestational diabetes mellitus (GDM) was associated 
with an increased risk of obstructive uropathy  [91] . 
Among a Pima Indian population with type 2 diabetes 
(aged 12–77 years), the OR for albuminuria in those who 
were the offspring of mothers with diabetes mellitus com-
pared with mothers with prediabetes was 3.8 (95% CI, 
1.7–8.4), and the age- and sex-adjusted incidence rate for 
ESKD in this population was 4.12 (95% CI, 1.54–11.02) 
 [26, 95] . As maternal diabetes and maternal obesity are 
both increasing worldwide and are highly correlated with 
each other, the impact of these conditions on the blood 
pressure and renal health of future generations is likely to 
increase  [96–98] .
 Clinical Associations of Renal Programming with 
ESKD 
 Several large studies have demonstrated associations 
specifically between LBW and the risk of ESKD  [16, 39] . 
The strongest evidence probably comes from a Norwe-
gian birth registry study where birth weight <10th per-
centile for the population (around 2.8 kg) was associated 
with a relative risk (RR) of 1.7 (95% CI, 1.4–2.2) for ESKD 
during the first 38 years of life  [86] . In separate analyses 
with LBW defined as <2.5 kg, even stronger effect esti-
mates were seen  [29] . This dose-response relationship 
suggests that the degree of IUGR is an important pro-
gramming factor  [29] ( Table 4 ).
 LBW was associated with an increased risk of ESKD 
due to any cause. The association was, however, stronger 
in the first 15 years of life and was strongest for congen-
ital malformations/hereditary diseases  [48] . Taking this 
further, an investigation into the programmed risk in a 
subgroup aged 18–42 years, excluding subjects with con-
genital renal disease, found that LBW per se was not sig-
 Table 4.  Risk of ESKD according to birth weight and gestational age category [derived from 29]
All 1 – 18 years  >18 – 42 years
HR 95% CI HR 95% CI  HR 95% CI
LBW
All (BW <10%ile) 1.63 1.29 – 2.06 2.72 1.88 – 3.92 1.23 0.9 – 1.68
<2.5 kg 2.25 1.59 – 3.19
SGA (all; <37 weeks) 1.67 1.3 – 2.07 1.93 1.28 – 2.91 1.53 1.15 – 2.03
Preterm (<37 weeks) 1.36 0.94 – 1.99
LBW
Term 1.56 1.18 – 2.07
Preterm 1.89 1.25 – 2.86 1.42 0.82 – 2.48
Term SGA 1.54 1.2 – 1.96 1.41 1.05 – 1.90
Preterm
AGA 1.09 0.69 – 1.73
SGA 4.03 2.08 – 7.80 4.02 1.79 – 9.03
 AGA, appropriate for gestational age; BW, birth weight; HR, hazard ratio; LBW, low birth weight; SGA, small 
for gestational age. All comparisons for term birth, LBW term, AGA term as relevant. 
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nificantly associated with developing ESKD, but being 
SGA was  [29] . In these studies, LBW, SGA, and preterm 
birth were overlapping groups. When using the defini-
tion of <10th percentile of birth weight for LBW and 
<10th percentile weight for gestational age for SGA, 
among the 10% with LBW, 61.0% had SGA, and 31.7% 
were preterm. When using the 2.5-kg cutoff for LBW, 
52% were also considered SGA, and 65.6% were preterm 
 [29] . Although LBW can be explained simply by short 
gestational age in prematurity, SGA is more often ex-
plained by intrauterine nutritional restriction. It is pos-
sible, therefore, that being SGA and/or being preterm 
are better markers for an adverse intrauterine environ-
ment. Previous studies have suggested LBW, SGA, and 
preterm birth are all associated with hypertension, pro-
teinuria, and a reduced GFR  [21, 22, 30–32, 87] . Indeed, 
in the Norwegian study cited above, among those 18–42 
years old, being SGA (birth weight <10th percentile for 
gestational age) was significantly associated with the risk 
of ESKD, and the effect was much stronger in those born 
preterm with SGA than those born at term with SGA 
(RRs of ESKD of 4.02 [95% CI, 1.79–9.03] and 1.41 [95% 
CI, 1.05–1.9], respectively;  Table 4 )  [29] . These popula-
tion level data suggest that both SGA and prematurity 
are important risk factors and likely potentiate each oth-
er’s effects, with preterm SGA infants being at highest 
risk.
 Maternal Nutrition and Health, Pregnancy 
Outcomes, and the Intergenerational Impact of 
Programming 
 Maternal health and nutrition are important determi-
nants of healthy pregnancies and impact kidney develop-
ment  [15, 99] . These factors are strongly impacted by so-
cioeconomic and structural factors  [65, 100] ( Table 5 ).
 Throughout life, maternal nutrition is an important 
determinant of pregnancy outcome and offspring birth 
weight ( Table 6 ).
 Short maternal stature is a risk factor for offspring 
SGA or preterm birth, and may result from the mother 
herself having been born preterm or SGA  [104, 105] . In 
animal studies, deficiencies in total calorie, protein/ami-
no acid, iron, vitamin A, and zinc intake in pregnancy 
have been associated with reduced nephron numbers in 
offspring [reviewed in  15 ]. In humans, mothers being un-
derweight or iron deficient during pregnancy have an in-
creased risk of having an LBW infant  [103] . Maternal vi-
tamin A levels have been shown to correlate with off-
spring kidney size and nephron number  [15, 106] . 
Supplementation of iron, micronutrients, balanced en-
ergy, calcium, zinc, and iodine in pregnant women have 
all been associated with reductions in LBW or preterm 
birth and, therefore, may have a positive impact on devel-
opmental programming in the kidney  [103, 107] . Mater-
nal intake of alcohol, caffeine, as well as tobacco con-
sumption are also known to be associated with an in-
creased risk of LBW, preterm birth, as well as program-
ming of childhood blood pressure, kidney size, and func-
tion  [108–115] . Interventions to reduce smoking in preg-
nancy have been associated with reductions in the risk of 
LBW and preterm birth  [107] .
 Table 5.  Maternal factors that modify a healthy pregnancy and 
comments [reprinted with permissions from 15]
 Developmental factors
 Maternal birth weight <2.5 or >4.0 kg
Short stature, stunting (height <145 cm)
Behavioral factors
Cigarette smoking
Alcohol consumption
Substance and/or drug abuse
Demographic factors
Age <18 or >40 years
Ethnicity
Health-related factors
Undernutrition, low maternal body mass index
Iron deficiency
Malaria
Diabetes mellitus or gestational diabetes mellitus
Hypertension
Preeclampsia, eclampsia
Chronic kidney disease, transplant, dialysis
Birth before term
Multiple gestations
Multiparous (≥3)
Assisted reproduction
Infections
Obesity
Social factors
Highly active antiretroviral therapy for HIV 
Prenatal care
Unplanned pregnancy, birth spacing
Teenage pregnancy
Marriage during childhood
Conflict, war, stress
Education level
Poverty
Environmental factors
Seasonal variations in nutrient availability
Toxin or pollutant exposure
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 Chronic maternal illness and acute infections increase 
the maternal risk of LBW, SGA, preterm birth, and pre-
eclampsia  [15, 116, 117] . Acute infections such as ma-
laria are an important cause of LBW, SGA, and preterm 
birth, which was estimated to contribute to 900,000 LBW 
deliveries in sub-Saharan Africa in 2010  [118] . Registry 
data from Denmark reported an increase in maternal 
chronic disease in pregnancy from 3.71 to 15.76% be-
tween 1989 and 2013  [119] . A population survey in Ger-
many reported 20% of pregnant women having at least 1 
chronic disease, which was associated with an increased 
risk of preterm delivery  [120] . Specifically, women with 
all stages of CKD in pregnancy have increased risks of 
preterm birth, SGA, and LBW, which increase with wors-
ening renal function  [121, 122] . The major maternal risk 
factors for preeclampsia identified in a secondary analysis 
of the WHO Global Survey on Maternal and Perinatal 
Health included chronic hypertension, GDM, cardiac 
disease, renal disease, urinary tract infections, pyelone-
phritis, and severe anemia  [123] . Among these, chronic 
hypertension had the highest OR (7.75; 95% CI, 6.77–
8.87) followed by cardiac/renal disease (OR 2.3; 95% CI, 
1.86–3.05), and GDM (OR 2.00; 95% CI, 1.63–2.45). In 
turn, the odds of offspring preterm birth (2.86; 95% CI, 
2.68–3.06) and LBW (OR 2.32; 95% CI, 2.16–2.50) were 
significantly increased in pregnancies complicated by 
preeclampsia.
 A mother’s own birth history and circumstances im-
pact her risk of pregnancy complications. The risk of 
GDM or gestational hypertension including preeclamp-
sia or eclampsia was significantly increased in women 
who themselves were born preterm  [124] . The risk in-
creased with decreasing gestational age and with super-
imposed SGA, again demonstrating a dose-response re-
lationship with the degree of prematurity and the impact 
of growth restriction on long-term risk (OR for  ≥ 1 com-
plication 1.95; 95% CI, 1.54–2.47, if the mother was born 
<32 weeks, and 1.14; 95% CI, 1.03–1.25, if the mother was 
born between 32 and 36 weeks). Preeclampsia is associ-
ated with an increased risk of LBW, SGA, and preterm 
birth  [123] . Based on the programming paradigm, the 
offspring of these pregnancies in turn would be at in-
creased risk of pregnancy complications, perpetuating 
the intergenerational cycle of developmental program-
ming. Similarly, maternal LBW or prematurity are risk 
factors for LBW or preterm infants. Interestingly, the risk 
of offspring prematurity was significantly increased if the 
mother was premature, in inverse proportion to her ges-
 Table 6.  Global distribution of maternal nutritional indices
Obesity Anemia (defined as hemoglobin <110 g/L) 
(2011)
Vitamin A deficiency
(1995 – 2005)
Global 
prevalence
11% 38% (34 – 43) 15.3% 
(7.4 – 23.2)
HIC USA (2011 – 2012): 31.8% (28.3 – 35.5) 22% (16 – 29)
European region (2009): 7.1 – 25.2%
LMIC European region (2003 – 2012): 5.0 – 21.2% Central and Eastern Europe: 24% (14 – 40)
Eastern Mediterranean region (2003 – 2013): East and Southeast Asia: 25% (17 – 38)
9.7 – 31.0% Oceania: 36% (18 – 59)
African region (2004 – 2012): 0.7 – 26.8% South Asia: 52% (40 – 63)
American region (2008 – 2012): 6.4 – 26.3% Central Asia, Middle East, and North Africa: 
Southeast Asian region (2006 – 2011): 31% (22 – 42)
0.9 – 12.1% Central and West Africa: 56% (46 – 62)
East Africa: 36% (30 – 41)
South Africa: 31% (20-48%)
Andean and Central Latin America and 
Caribbean: 27% (21 – 34)
Southern and Tropical Latin America: 
31% (13 – 56)
Reference 101 102 103
 HIC, high-income country. Numbers in parentheses are study durations and 95% confidence intervals. Vitamin A deficiency was 
defined as serum retinol <70 μmol/L.
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tational age, but was not increased if the father was born 
preterm, suggesting a direct programming effect in the 
mother  [125] . Maternal obesity is a risk factor for both 
HBW and LBW, and maternal diabetes increases the risk 
for HBW in the offspring. These outcomes associate with 
renal developmental programming  [100] . Importantly, 
the risk of LBW was highest in mothers who had been 
born preterm but became obese before pregnancy, again 
indicating the compounding hazard of obesity after being 
born small  [126] . Both maternal LBW or HBW was also 
associated with an increased risk of GDM  [127] . Whether 
all of these intergenerational risks transmitted through 
developmental programming and alterations in offspring 
phenotype are mediated directly or via epigenetic mecha-
nisms is not yet clear and requires further study  [46, 128–
130] .
 The majority of maternal factors impacting LBW and 
prematurity do not exist in isolation. Their developmen-
tal effects on the kidney are highly relevant for women in 
developing countries, where the prevalence of SGA in-
fants, preterm birth, and LBW infants is known to be 
higher than in developed countries, but also remain 
highly relevant in developed countries with increasing 
maternal age, more frequent maternal chronic disease, 
and use of assisted reproduction technologies (ART) 
( Fig. 2 ).
 Renal Programming and Congenital Anomalies of 
the Kidneys and Urinary Tract 
 Congenital anomalies of the kidneys and urinary tract 
(CAKUT) account for 50% of pediatric kidney trans-
plants, with obstructive nephropathy and hypoplasia/
dysplasia constituting the majority of these  [131] . Mono-
genic mutations have been established in approximately 
17% of CAKUT, but, in most cases, the etiology remains 
undetermined and is likely the result of multiple genetic, 
epigenetic, and fetal environmental factors. In a recent 
population-based case-control study of children <21 
years of age with CKD, LBW (OR 4.51; 95% CI, 3.47–
5.85) and maternal pregestational diabetes (OR 7.52; 95% 
CI, 3.97–14.24) were significantly associated with the risk 
of renal dysplasia or aplasia  [91] . Similarly, maternal 
GDM (OR 1.50; 95% CI, 1.07–2.09), maternal overweight 
(OR 1.27; 95% CI, 1.05–1.52), maternal obesity (OR 1.27; 
95% CI, 1.05–1.55), and LBW (OR 2.53; 95% CI, 1.95–
3.29) were all significantly associated with childhood ob-
structive uropathy  [91] . Many gestational stress factors 
can, therefore, potentially impact renal development.
 An important but underrecognized clinical correlate 
of reduced nephron numbers is congenital urinary tract 
obstruction. Animal models have been developed to ex-
amine the relationship of kidney development to injury 
resulting from urinary tract obstruction. In contrast to 
 Fig. 2. Prevalence of SGA, preterm birth, and LBW infants by United Nations Millennium Development Goal 
regions in 2010 (reprinted with permission  according to CC Creative Commons Attribution-NonCommercial-
noDerivs from Lee et al.  [28] ). 
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humans, in whom all nephrons are formed before birth, 
nephrogenesis continues in the first postpartum week in 
rats and mice. Surgical unilateral ureteral obstruction 
(UUO) in the early postnatal period, therefore, models 
obstruction in the human third-trimester pregnancy. 
Complete UUO in the newborn rat reduced nephron 
number by 40%: release of obstruction after 5 days nor-
malized GFR at 1 month of age, but did not restore neph-
ron number  [132] . When these rats were followed to 1 
year of age, nephron number remained 40% of normal, 
but GFR of the postobstructed kidney decreased by 80%, 
and glomerular sclerosis and interstitial fibrosis were in-
creased in both kidneys  [133] . There is a linear correla-
tion between the duration of UUO and the nephron num-
ber reduction in the neonatal rat  [134] . In contrast to the 
neonate, however, release of complete UUO in the adult 
rat does not result in a decreased nephron number  [134] . 
These studies suggest that the developing kidney is par-
ticularly susceptible to obstructive injury, and that early 
surgical release of urinary tract obstruction can improve 
long-term nephron number.
 In most children requiring RRT for CAKUT, the onset 
of renal failure is delayed until adulthood  [135] .  Nephron 
number at birth may, therefore, be an important determi-
nant of outcome after relief of congenital obstruction and 
a modulator of the decline in renal function over time. 
Consistent with this possibility, the risk of ESKD was 
found to be significantly higher among SGA subjects with 
CAKUT or inherited causes of renal disease compared to 
those with normal birth weights (OR 2.5; 95% CI, 1.6–3.7) 
 [86] .
 Neonatal AKI and Perinatal Drug Exposure 
 AKI occurs in 16–70% of neonatal populations  [136–
138] . Some of this variability comes from reports of neo-
nates and preterm infants with varying comorbidities 
(e.g., congenital diaphragmatic hernia, cardiac surgery, 
and asphyxia) but also reflects the challenge of diagnosing 
AKI in the neonate and the lack, until recently, of a uni-
form diagnostic classification  [136] . A neonatal KDIGO 
classification has been proposed, but serum creatinine 
may not be reliable as it reflects maternal creatinine and 
is also dependent on maturity of renal tubule function 
 [136] . Cystatin C levels may reflect renal function better 
than creatinine, and various biomarkers are being inves-
tigated as a tool to detect AKI early  [139, 140] . The major 
risk factors for neonatal AKI are preterm birth, LBW, re-
duced nephron numbers, critical illness, and nephrotoxin 
exposure  [58, 136, 141–143] . All of these factors in turn 
may also reduce the potential for postnatal nephrogene-
sis, which can occur for a limited period following pre-
term birth  [58] .
 The kidney is vulnerable to the toxic effects of many 
drugs  [144] . Preterm neonates are often exposed to po-
tentially nephrotoxic drugs during ongoing renal devel-
opment  [141] . Aminoglycosides are frequently prescribed 
in the neonatal intensive care unit (ICU) and can lead to 
tubular injury and AKI  [144–147] . Furthermore, in ani-
mals, aminoglycosides have been shown to lead to re-
duced nephron numbers  [148, 149] . Nonsteroidal anti-
inflammatory drugs (NSAID) are used to treat patent 
ductus arteriosus (a congenital defect of the heart) in the 
postnatal period, and, particularly in preterm infants, this 
can potentially impact ongoing nephrogenesis and nega-
tively influence short-term renal function  [150] . The true 
risk of AKI in neonates exposed to nephrotoxic medica-
tions is not well described, however, as the toxicity cannot 
merely be extrapolated from knowledge in older children 
and adults. A prospective study of 269 infants exposed to 
medication perinatally (i.e., medication prescribed to 
mothers during late pregnancy or administered to the in-
fant within the first 7 days of life) and stratified according 
to whether they had a GFR below or above the group me-
dian on day 7 found that ibuprofen administration before 
day 7 was associated with an OR of 2.6 (95% CI, 1.2–5.3) 
for having a lower GFR  [151] . The lower GFR in infants 
administered ibuprofen persisted for the month of fol-
low-up. Importantly, aminoglycoside serum concentra-
tions were higher in infants receiving ibuprofen, suggest-
ing potentially enhanced toxicity  [151] . Exposure to ami-
noglycosides was not associated with a lower GFR in this 
study although 7 days could be too soon to detect an ef-
fect. Others have reported higher serum creatinine values 
at 2 months of age in preterm infants born SGA who re-
ceived aminoglycosides compared with those who did 
not  [152] . Given that many infants receive multiple med-
ications, and that infants with the lowest birth weights 
tend to receive more nephrotoxic medications per day, 
increased awareness of risks and of potential interven-
tions to minimize the risk of toxicity are crucial  [136, 141, 
146, 147] . A medication that is frequently used in the neo-
natal ICU that may be protective against AKI is caffeine, 
but more study is required to better determine the true 
effect  [153] . Current guidelines recommend prophylactic 
administration of theophylline, pharmacologically simi-
lar to caffeine but with a greater side effect profile, to in-
fants at high risk of AKI after perinatal asphyxia  [154] .
 Medications given to mothers before delivery have 
also been associated with an impact on neonatal renal 
function. Tocolytic therapy administered to the mother 
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until the day of delivery was significantly associated with 
a lower GFR in the infant on day 7, and administration of 
the COX-2 inhibitor nimusulide as a tocolytic has been 
reported to induce renal failure and ESKD in neonates in 
multiple case reports  [151, 155, 156] . In animals, multiple 
medications that could be prescribed during pregnancy 
have been found to impact offspring kidney develop-
ment, including β-lactam antibiotics, cyclosporine, and 
long-term steroids, although their renal impact in hu-
mans is largely not known and long-term follow-up is 
needed  [48, 65, 157] . In humans, antibiotic treatment 
during pregnancy has also been associated with LBW, al-
though the effect was strongest for the nonpenicillins 
 [158] .
 The risk of neonatal AKI increases with increasing de-
gree of prematurity, demonstrating a dose-response ef-
fect in the susceptibility of the developing kidney to in-
jury  [159] . Neonatal AKI is associated with poor short-
term outcomes, such as increased mortality and longer 
hospital stays  [159, 160] . In addition to the association 
between neonatal AKI and short-term outcomes, AKI is 
linked to the development of CKD both in epidemiology 
studies and in studies of LBW subjects (weighing <1.5 or 
1.0 kg), an effect that may be modulated by the develop-
ment of obesity  [20, 161–164] . There is academic debate 
surrounding the pathway linking AKI and CKD. Some 
believe AKI permanently damages nephrons, and this re-
duction in nephron numbers causes CKD. Others believe 
AKI is a “red flag” or a harbinger for patients at risk, with 
a reduced number of nephrons, and these patients were 
destined to develop CKD. In either case, AKI may be a 
potentially modifiable risk factor for later-life CKD  [165] . 
Importantly, it has been reported that episodes of AKI 
occurring during neonatal hospitalization are often not 
recorded in hospital discharge letters  [159] . Such infor-
mation is crucial to communicate as ongoing follow-up 
of infants with AKI is necessary.
 LBW Is Associated with More Rapid Progression of 
CKD 
 It is unlikely that developmental changes in the kidney 
associated with LBW, prematurity, or other developmen-
tal stressors alone are enough to lead directly to renal dis-
ease except in severe cases, but a kidney with fewer neph-
rons would plausibly be less able to withstand additional 
“hits” such as AKI, glomerulonephritis, or renal injury 
imposed by other developmentally programmed condi-
tions such as diabetes, CVD, and obesity, which all exac-
erbate the risk of renal injury  [20, 23, 166, 167] ( Fig. 3 ).
 IgA nephropathy (IgAN), for example, is the most fre-
quent primary idiopathic glomerulonephritis worldwide 
 [168–170] . Patients with IgAN tend to be younger and 
 Fig. 3. Multi-hit nature of renal disease programming (reprinted with permission from Luyckx et al.  [65] ). 
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have fewer confounding conditions than other CKD pa-
tients, but they are at risk of rapid disease progression. 
IgAN is therefore a good model to study the impact of 
renal programming. Lower glomerular density has been 
shown to predict the long-term prognosis of IgAN  [171] . 
In children with IgAN, LBW was associated with higher 
rates of progressive disease  [172] . In a further analysis of 
a Norwegian population-based study, LBW and SGA 
were independently associated with an increased risk of 
reaching ESKD in adult males (OR 2.2; 95% CI, 1.1–4.4, 
and OR 2.7; 95% CI, 1.4–5.5) compared to controls; how-
ever, the risk was further increased among those with 
both LBW and SGA (OR 3.6; 95% CI, 1.6–8.2)  [173] . 
There were no associations found between birth param-
eters and ESKD among females, but the numbers were 
small and statistical power was limited. Preterm birth 
alone was also not associated with ESKD risk in this study, 
and among those born SGA, those born preterm had a 
higher risk of developing ESKD (OR 10.8; 95% CI, 2.6–
4.5) than those born at term  [173] . In this study, IgAN 
patients with LBW/SGA had lower estimated GFR at the 
time of diagnosis, and, after adjustments for this, the as-
sociation was no longer significant  [173] . Exactly how 
LBW/SGA modulates the risk of renal disease progres-
sion in IgAN is thus not yet clear, although unpublished 
data show that the patients with LBW/SGA had larger 
glomerular volumes, potentially consistent with reduced 
nephron numbers. Other studies have also shown more 
rapid progression of other primary renal diseases in hu-
mans associated with LBW  [174–181] ( Table 7 ).
 Aging and Programming of Renal Disease 
 Observational data in humans show that GFR normal-
ly declines with age, usually beginning after about 30 
years of age, but at variable rates  [183, 184] . Such decreas-
es in GFR are seen in the healthiest of the healthy (living 
kidney donors)  [185] . In normal subjects studied longi-
tudinally, the distribution of the slopes of change in renal 
function over time is nearly Gaussian, with an increased 
rate of decline in the “tail”  [183] . The changes in GFR 
with aging can be dissociated from blood pressure and 
cardiovascular function  [186] . The variability in the rate 
of “renal senescence” might be traceable to renal endow-
ment. If renal senescence, whatever the mechanism, is a 
programmed phenomenon, then it is reasonable to pos-
tulate that the number of nephrons present at the begin-
ning of life will directly influence the rate of GFR decline 
with aging. Indeed, experimental data in animals have 
suggested that inbred strains with impaired nephrogen-
esis develop glomerulosclerosis later in life  [187, 188] . Ex-
perimentally induced LBW and low nephron numbers 
are associated with the acquisition of an accelerated
“renal senescence” phenotype, especially after catch-up 
growth  [189–191] . Premature renal senescence may, 
therefore, be a programmed phenotype.
 The association between LBW and ESKD has not been 
studied in subjects older than 50 years apart from 1 Japa-
nese study suggesting that diabetic nephropathy was 
more common among elderly patients on hemodialysis 
who had been born with LBW  [16, 192] . Whether this 
finding suggests an effect of programming on diabetes, 
renal disease, or both, is not known  [29] . As the impact of 
prenatal programming is expected to be compounded 
with age, the association of LBW and SGA with the risk 
of ESKD seen in younger adults may become greater with 
age  [29] ( Table 4 ).
 Potential Effects of Programming on Kidney 
Transplantation 
 Kidney donation involves the loss of one half of exist-
ing nephrons. Donors having a single remaining kidney 
with a reduced number of nephrons per kidney may be at 
increased risk of loss of renal function over time  [193] . 
 Table 7.  Examples of primary kidney diseases that progress more 
rapidly in patients with low birth weight (LBW)
Clinical findings
IgA nephropathy [172, 173]
Increased hypertension and glomerulosclerosis in LBW children
Increased progression to end-stage renal disease if LBW and/ or 
small for gestational age, especially among males
 Membranous nephropathy [181]
LBW associated with steeper decline in glomerular 
filtration rate
Minimal change disease [172, 174, 177]
More relapses and steroid dependence in LBW children 
Chronic pyelonephritis [179]
Patients with progressive deterioration in renal function had 
lower birth weight
Autosomal dominant polycystic kidney disease [178]
Earlier onset of end-stage renal disease with lower birth weight
Focal-segmental glomerulosclerosis [180]
Very LBW and preterm birth are risk factors for focal-segmental 
glomerulosclerosis
Alport syndrome [182]
More rapid progression in LBW identical twin
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Animal studies have demonstrated that a reduction in re-
nal mass in rats with congenitally reduced nephron num-
bers leads to accelerated loss of renal function compared 
to similar renal mass reduction in genetically identical 
rats with normal nephron numbers  [187] . These data are 
relevant to both transplant recipients and kidney donors. 
In recipients, mismatch of kidney size to donor size, i.e., 
smaller kidneys transplanted into larger donors, is associ-
ated with accelerated loss of renal function over time 
 [194, 195] . It is conceivable that kidneys from donors 
with low nephron numbers would be at the highest risk 
of failure  [196] . Nephron numbers in donated kidneys 
have not been studied, but smaller kidneys, by weight or 
volume, which are proportional to nephron number, 
have been shown to have shorter graft survival  [197–199] . 
Similarly, a donor with a reduced nephron number may 
also be at increased risk of loss of renal function over time 
with a single kidney  [193] ( Table 8 ).
 Similarly, women who have experienced preeclampsia 
are themselves at increased risk of developing ESKD, a 
risk which may increase after the donation of 1 kidney 
 [204] . Indeed, women with preeclampsia have a 4- to 15-
fold increased risk of all-cause ESKD compared to wom-
en without preeclampsia  [86, 205] . The risk was highest 
in women who also gave birth to offspring with LBW, in 
women with only 1 lifetime pregnancy and in women 
with recurrent preeclampsia.
 Programmed Risk of Hypertension and Kidney 
Disease May Be Different for Different Ethnic Groups 
and Socioeconomic Environments 
 Hypertension and renal disease prevalence vary be-
tween populations from different ethnic backgrounds, 
with very high rates being observed among Aboriginal 
Australians, Native Americans, and people of African de-
scent  [26, 40, 206] . Renal programming has largely been 
studied in western Caucasian populations; therefore, the 
impact of developmental programming of hypertension 
and kidney disease in high-risk populations, although 
suggestive, has not been comprehensively studied  [66, 
207] . The incidence rates of major risk factors for devel-
opmental programming of CKD in LMIC are highlighted 
in  Table 9  [20] .
 For example, only 3.3% of subjects in a Norwegian 
study on the association of birth weight with ESKD had 
birth weight under 2.5 kg, whereas LBW in sub-Saharan 
Africa has an incidence of 13–15%  [3, 29] . In lower-in-
come countries, maternal undernutrition is a significant 
contributor to IUGR, whereas in higher-income coun-
tries multiple gestations, ART use, and placental insuffi-
ciency are more frequent causes  [117, 208, 209] . It is not 
known whether the varying causes of IUGR affect neph-
ron development similarly or not. Importantly, however, 
maternal undernutrition in lower-income countries may 
be a frequent cause of impaired nephron development 
and may impact the future risk of renal disease and high 
blood pressure in these populations  [15, 210] .
 Hoy et al. [211, 212] have described a strong and con-
sistent association between LBW, reduced nephron num-
bers, hypertension, susceptibility to renal disease, and 
premature death in the Australian Aboriginal population, 
in which LBW is more prevalent and socioeconomic dis-
advantage is greater than in their white counterparts. 
How observations of developmental programming apply 
from one population to another, however, has not been 
well studied and may be different. In India, for example, 
 Table 8.  Hypertension and renal function in living kidney donors at risk of renal programming
Population US [200] Australia [201] Canada [202]  Germany [203]
black donor/
nondonor
white donor/
nondonor
indigenous 
donors
nonindigenous 
donors
aboriginal 
donors
white 
donors
BW 
≤2 .5 kg
BW 
>2.5 kg
Donor number 12,387 71,769 22 28 38 76 18 73
Population 
programming risk 
factors
LBW prem. LBW Ref HBW (offspring 
DM pregnancies)
Ref LBW Ref
HT – – 50% 6% 42% 19% 39% 15%
Proteinuria – – 81% 6% 21% 4% 81% 35%
↓ GFR – – 81% 38% Not different Not different
ESKD 74.7 vs. 23.9/
10,000
22.7 vs. 0.0/
10,000
19% 0% 1 0 0 0
Follow-up, 
years (IQR)
7.6 
(3.9 – 11.5)
16.1 
(1.27 – 20.2)
6.37 
(2.54 – 21.2)
14.6 ± 9.3 13.4 ± 9.5 ≥5 ≥1 – 3
 BW, body weight; DM, diabetes mellitus; ESKD, end-stage kidney disease; GFR, glomerular filtration rate; HBW, high birth weight; HT, hypertension; LBW, low birth weight; Ref, 
referring group.
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LBW is common and has also been associated with high-
er blood pressure in some studies, but the programming 
effects appear to be more consistent for insulin resistance 
and type 2 diabetes in this population, possibly modu-
lated by the “thin-fat” phenotype  [213] . As discussed 
above, the inverse relationship between nephron num-
bers and blood pressure observed in Aboriginal Austra-
lians was similar to that seen among Caucasian Ameri-
cans, but not as evident in African-Americans  [66] . Sim-
ilarly, the relationship between LBW and blood pressure 
is more consistently shown in Caucasian than African-
American children  [214, 215] .
 An increase in blood pressure among adults exposed 
to famine during gestation and early development was, 
however, found to be similar among Nigerians exposed 
to the Biafran famine (1967–1970) and those exposed to 
the Dutch famine (1944–1945)  [216, 217] . Among Bia-
fran subjects, studied at age 37–43 years, fetal and infant 
exposure to famine was associated with an increased risk 
of hypertension (OR 2.87; 95% CI, 1.9–4.34) compared to 
those born after the famine  [216] . Among Dutch subjects, 
studied at age 59 years, the risk of hypertension was in-
creased after exposure to famine for 10 weeks or more 
(OR 1.44; 95% CI, 1.04–2.0) compared to unexposed sub-
jects  [217] . Earlier analysis in the Dutch subjects between 
ages 48–53, however, did not find significant differences 
in blood pressure among those exposed or not exposed to 
famine  [218] . The effect of famine on blood pressure may, 
therefore, be accelerated in the African compared with 
the European populations, which suggests that addition-
al factors likely contribute to hypertension in African 
populations. In both studies, exposed compared with 
nonexposed subjects also had increased risks of obesity 
and glucose intolerance in adulthood, demonstrating the 
multisystem impact of developmental programming 
 [216, 218] .
 Although the prevalence of childhood undernutrition is 
declining, the global estimate for childhood wasting in 
2011 was still 8%, of whom 70% lived in Asia  [103] . The 
long-term consequences of infant malnutrition on blood 
pressure and renal function have been scarcely studied. 
Among African-Caribbeans aged 28 years who survived 
Kwashiorkor or Marasumus, exposure to infant malnutri-
tion was associated with alterations in cardiac function, 
higher systemic vascular resistance, and increased diastol-
ic blood pressure  [219] . These data emphasize the impor-
tance of early childhood nutrition in modulating CVD risk 
and highlight the need for further studies to understand 
the pathophysiology and determine how best to intervene.
 At present, there is also compelling evidence of an as-
sociation between variants in the apolipoprotein L1 
(APOL1) gene and CKD in African-Americans and in 
West Africans  [220–222] . A key question is whether these 
variants interact with LBW in a way that influences the 
development of CKD given that LBW is prevalent in sub-
Saharan Africa and among African-Americans compared 
to their Caucasian counterparts  [34, 223] . The relation-
ship between nephron number and birth weight in sub-
jects of African origin has been found to be consistent 
with that seen in Caucasian subjects; therefore, despite 
studies in adults with unknown birth weights showing a 
large variation in nephron numbers among African-
Americans, with the mean being similar between Cauca-
sians, African-Americans, and Senegalese, LBW is likely 
associated with reduced nephron numbers  [60, 61, 224, 
225] . One study reported that African-Americans with 
1–2 APOL1 variant alleles did not have fewer glomeruli 
or larger glomeruli than African-Americans without risk 
alleles, but kidneys from subjects with 1–2 APOL1 risk 
variants experienced accelerated loss of nephrons after 
age 38 years, which was further increased by concurrent 
obesity  [226] . This possible interaction between APOL1 
Fetal/maternal circumstances Proportions in LMIC
LBW (2010) 15% (138 LMICs)
Prematurity (2010) 11.3% (138 LMIC)
HBW (2004 – 2008) 0.5 – 14.9% (24 countries)
Gestational diabetes (2013) 0.4 – 24.3% (15 countries)
Maternal overweight (2003 – 2009) 13.7% (27 sub-Saharan countries)
Maternal obesity (2003 – 2009) 5.3% (27 sub-Saharan countries)
 HBW, high birth weight; LMIC, low- and middle-income countries. In gestational 
diabetes, rates vary in part related to differences in cutoff values for diagnosis.
 Table 9.  Prevalence of LBW, prematurity, 
maternal diabetes, and obesity in low- and 
middle income countries [18, 28, 96, 97]
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risk variants and the effect of LBW on kidney disease in 
these ethnic groups needs further investigation.
 Catch-Up Growth and Nutrition in Early Childhood 
as Modulators of Developmental Programming 
 Postnatal nutrition also has potential programming 
consequences. Especially in preterm infants or those born 
SGA, optimal early nutrition is important for growth and 
survival  [227] . Through experimental and human stud-
ies, it has been shown that postnatal nutrition in terms of 
calories, protein content, and micronutrients can impact 
nephron numbers and long-term renal function  [15, 20, 
31, 82, 83, 228–230] . Animal data suggest some reversal 
of programmed renal changes can occur with the restora-
tion of normal dietary composition, but overfeeding leads 
to obesity and hypertension independently of nephron 
numbers and may therefore be harmful  [83, 228] . In pre-
term children studied at age 7 years, both intra- and ex-
trauterine growth restriction were associated with re-
duced GFR (although still within the normal range),
suggesting an impact of postnatal growth restriction
on kidney development  [31] . Optimizing postnatal nutri-
tion in preterm infants is a challenge.
 Evidence is mounting to show that rapid “catch-up” 
growth (i.e., upward crossing of weight centiles) or in-
crease in BMI leads to the development of higher blood 
pressure, insulin resistance, and cardiovascular risk al-
ready in childhood  [231–233] . These findings are most 
marked in those who were born small and became rela-
tively larger  [213, 231, 234, 235] . In resource-limited coun-
tries, catch-up growth is necessary as it improves child
survival, stunting, and malnutrition  [227] . The timing of 
catch-up growth appears to modulate the risk/benefit ra-
tio, as early catch-up seems beneficial and later catch-up 
appears to be more harmful  [227, 233, 234, 236] . The ef-
fects of catch-up growth may be different if the catch-up 
occurs predominantly in height (linear growth) or in 
weight, and, in most studies, the adverse effects were most 
marked among those who had been LBW or preterm and 
became overweight or obese  [233–237] . Effects of catch-up 
growth may also differ between developed and developing 
countries  [238] . HBW and exposure to GDM are also risk 
factors for childhood overweight and obesity  [239] .
 It has been suggested that in individuals born small 
(LBW, SGA, or preterm), the superimposition of a high 
metabolic demand from a large body on a relatively small 
kidney may be a factor leading to hypertension and kid-
ney disease over time  [75] , termed the “capacity load” 
model. Indeed, in a pediatric renal clinic population, chil-
dren who were preterm and became obese had more rap-
id progression of renal disease compared to similar pre-
term children who were not obese  [240] . In a separate 
cohort, in a follow-up of extremely LBW preterm chil-
dren who had experienced neonatal AKI, GFR were low-
er at age 7.5 years among those with elevated BMI  [241] . 
In a population study where birth weights were unknown, 
obesity in adolescents was found to be a risk factor for 
later-life ESKD  [242] . Finding the inflection point where 
postnatal nutrition is optimal to improve short-term sur-
vival and not increase the long-term risk of CVD is an 
ongoing challenge. It would seem that close monitoring 
of growth trajectories in early life and life-long preven-
tion of overweight and obesity through education, diet, 
and exercise in those born small is a safe and achievable 
principle  [243, 244] .
 Nature versus Nurture in the CKD Developmental 
Programming Debate 
 There has been ongoing debate as to the underlying 
causes of the associations between LBW and later hyper-
tension and kidney disease  [245–247] . The relationship 
between birth weight and nephron number and the asso-
ciations between intrauterine malnutrition and cardio-
vascular risk factors suggest a direct programming effect 
signaled by growth restriction  [59, 82, 248–250] . On the 
other hand, LBW, CVD, and CKD do aggregate in fami-
lies, suggesting possible genetic or environmental factors 
determining or confounding the association  [247, 251–
255] . The association between LBW and hypertension 
has been studied the most. A meta-analysis of small twin 
studies suggested that family factors do confound the re-
lationships, but a large Swedish twin study suggested fetal 
growth was the most dominant programming factor  [245, 
256, 257] . In another study, higher blood pressure, BMI, 
and dyslipidemia in the father were found to be associ-
ated with LBW, which may also support genetic or envi-
ronmental causes  [258] . A recent follow-up Norwegian 
study examined the potential familial confounding of the 
association between LBW and ESKD risk  [29] . In this 
study, the positive association between being LBW or 
SGA and later ESKD risk was not significantly modified 
by having a sibling with LBW or SGA. This study, there-
fore, argues that LBW or SGA per se have a greater impact 
compared to familial factors. Twin studies of renal func-
tion have also shown a lower GFR and more rapid pro-
gression of inherited renal disease in the lower birth 
weight twin in both dizygotic and monozygotic twins, 
which argues for a greater impact of fetoplacental over 
genetic factors in renal developmental programming 
 [182, 259] .
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 Consensus Recommendations 
 What follows is the approach adopted by the Low Birth 
Weight and Nephron Number Working Group.
 Recommendation 1: On Maternal Preconception 
Health (Including Social Factors and Maternal 
Chronic Diseases) 
 Preconception Care and Embryonic Health 
 • Rationale 
 In addition to impacting fetal growth, maternal char-
acteristics, and to some extent paternal determinants, also 
affect gametogenesis and embryonic development  [3, 
260] , with a lasting impact on offspring health  [261, 262] . 
Prepregnancy underweight is associated with an increased 
risk of offspring SGA (OR 1.81; 95% CI, 1.76–1.87) and 
LBW (OR 1.47; 95% CI, 1.27–1.71)  [263] . Another study 
found a 32% increased risk of preterm birth in women 
who were underweight before conception  [264] . Over-
weight before pregnancy is associated with an increased 
risk of macrosomia (OR 1.67; 95% CI, 1.42–1.97)  [263] . 
The risk of preeclampsia and GDM increases around 
2-fold with maternal overweight before pregnancy  [264] . 
Weight loss before pregnancy has in some studies been 
associated with a reduced pregnancy risk in overweight 
women  [264] . Preconception care has been shown to im-
prove pregnancy outcomes  [264–266] , although it is im-
portant to recognize that up to 65% of preterm births re-
main unexplained  [267] . Counseling and optimization of 
maternal weight and nutrition, and avoidance of alcohol, 
tobacco, and caffeine before pregnancy, all have a positive 
impact on pregnancy outcomes. The risk of having a pre-
term birth or an SGA infant is increased in mothers with 
chronic diseases  [268] . Preconception care for women 
with underlying chronic diseases is crucial to plan a 
healthy pregnancy in terms of maximization of maternal 
health, making medication adjustments and timing of 
pregnancy  [269] . The prevalence of chronic diseases in 
women of reproductive age is not comprehensively de-
scribed globally, but it has increased in recent years and 
may be compounded by increasing maternal age  [119] . 
Significant regional differences exist in the prevalence of 
maternal diseases, for example diabetes mellitus, sickle-
cell disease, thyroid disease, and obesity, and, therefore, 
care should be tailored to regional needs  [270, 271] . In 
some cases, chronic diseases, e.g., diabetes or CKD, may 
also be associated with reduced fertility, which may delay 
pregnancy or increase the risk of complications  [90, 121] . 
A particular problem in many countries is teenage preg-
nancy, which, in many cases, is unplanned and may be as-
sociated with socioeconomic factors, poverty, lack of edu-
cation for girls, lack of access to family planning services, 
and child marriage. Interventions targeting birth spacing 
have been shown to reduce LBW and preterm birth  [272] . 
The rates of teenage pregnancy vary globally, with the 
highest rates of pregnancies in women/girls under age 19 
years being reported in Latin America (peak 288 per 1,000 
live births in Nicaragua)  [273] . Teenage pregnancies are 
associated with higher risks of preeclampsia, eclampsia, 
infections, anemia, LBW, and preterm birth  [272–274] . 
First or recurrent teenage pregnancy can be reduced by 
15–37% through implementation of comprehensive tar-
geted strategies  [272] . Preconception health is, therefore, 
not only related to obstetric and medical risk factors, such 
as chronic diseases, but also to lifestyle, education, work-
ing conditions, experience of violence, geography, and the 
socioeconomic status of women  [265, 266, 275] . Precon-
ception care, therefore, encompasses a multisectoral ap-
proach as highlighted in the Sustainable Development 
Goals (SDGs) to improve overall health, life choices, and 
opportunities for women, and can be delivered success-
fully at all tiers of the health system  [266] ( Fig. 4 ).
 • Recommendations for action 
 1 Implement comprehensive programs for general and 
specialist preconception care and education starting 
from school age girls, as the periconception period is 
one of the most critical periods in the life course  [97, 
261] .
 2  Deliver preconception counseling regarding dietary 
modification, weight management, physical exercise, 
and lifestyle choices to optimize future maternal and 
neonatal outcomes  [3, 276] .
 3 Identify and treat diseases and complications (e.g., 
preexisting diabetes, renal insufficiency, hypertension, 
anemia, and infections) that may affect maternal, fetal, 
and neonatal health before conception  [121, 269, 277–
281] .
 4 Implement routine preconception care in the imme-
diate postpartum period following every delivery or 
pregnancy loss (interconception)  [282] . This approach 
would have the following advantages/aims:
 (i) Most (relevant) women would be accessed.
 (ii) Health education would improve the health of 
young mothers but would also extend to their infants 
and families.
 (iii) Emphasize the importance of regaining pregesta-
tional weight as a simple and achievable goal, with 
proven benefits for future pregnancies and offspring 
 [283] , which can also be used as a justification for long-
term follow-up.
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 (iv) Health care workers can approach women from 
the perspective of “offering help” instead of “blaming 
them for their mistakes”.
 5 Institutions and governments should take nonmedical 
risk factors, such as those related to poverty (i.e., re-
ducing teenage marriage and pregnancies, access to 
education for girls, ensuring access to family planning 
to space pregnancies, and experience of violence) into 
account.
 6 Societal valorization programs of new knowledge to 
improve perinatal health should be initiated and sup-
ported by both universities and governmental bodies 
 [284] . 
 7 Local and WHO guidelines should be followed.
 Assisted Reproductive Technology 
 • Rationale 
 There is increasing evidence that infertility or subfer-
tility per se are independent risk factors for obstetrical 
complications and adverse perinatal outcomes, even 
without the addition of ART  [285] . Unadjusted analyses 
suggest a 2-fold increased risk of preeclampsia in sponta-
neous singleton pregnancies in women with a history of 
infertility compared with women in the general popula-
tion  [286] . Women requiring ART, therefore, appear to 
have an increased baseline risk for pregnancy-related 
complications. ART has been associated with preterm 
birth, LBW, and SGA  [287] . ART is becoming an increas-
ingly relevant cause of these complications in high-in-
come countries where, for example in Australia and Den-
mark, 4–5% of all births result from ART  [288] . Multiple 
gestation is the most powerful predictive factor for ad-
verse maternal, obstetrical, and perinatal outcomes in 
ART pregnancies  [289] . However, ART is also associated 
with an increased risk of preterm birth and LBW in sin-
gleton pregnancies  [290, 291] . Several studies report an 
increased risk of preeclampsia with ART. The odds of 
preeclampsia is significantly increased in women under-
going ART (OR 2.2; 95% CI, 1.03–4.72) after controlling 
for factors such as multiple gestations  [292] . A retrospec-
tive population-based study of singleton pregnancies 
conceived through in vitro fertilization (IVF) and ovula-
tion induction compared to spontaneously conceived 
pregnancies showed a significant linear association in the 
incidence of severe preeclampsia in the ART groups 
(2.7% in IVF, 1.8% in ovulation induction, and 1.1% in 
the comparison group, p < 0.001)  [293] . However, in an-
other study, using propensity score matching analysis, 
 Fig. 4. Different packages of preconception care interventions (reprinted with permission according to CC
Creative Commons Attribution-NonCommercial-noDerivs from Lassi et al.  [266] ). 
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the association between IVF and preeclampsia was found 
to be weaker than when conventional adjustments were 
made, suggesting potential confounding of the associa-
tion between IVF and preeclampsia by multiple factors 
 [294] . A recent meta-analysis found that the risk of pre-
eclampsia is 3-fold higher in pregnancies achieved by IVF 
with oocyte donation compared to with a woman’s own 
oocytes  [295] . The pathophysiological relationship be-
tween oocyte donation and preeclampsia remains un-
clear. An immunological theory based on the allogenicity 
of the fetus to the mother has been postulated, while oth-
er authors hypothesize that a patient needing oocyte do-
nation might also have an immunologically based condi-
tion that predisposes to preeclampsia  [295] . Given the
inherent risks of ART, preconception counseling and op-
timization of maternal health and nutrition prior to con-
ception are crucial, and “judicious use” of ART, including 
reduction in the number of embryos transferred, is pro-
posed as a strategy to reduce preterm births by as much 
as 63%  [209, 288] .
 • Recommendations for action 
 1 Women of reproductive age undergoing ART proce-
dures must be informed that these techniques are as-
sociated with an increased risk of preterm birth, LBW, 
and preeclampsia  [289–291] . 
 2 Routine preconception counseling is necessary to op-
timize maternal nutrition, weight, and lifestyle before 
conception.
 3 Women undergoing assisted reproduction procedures 
should receive more intensive monitoring during 
pregnancy.
 4 Reduction in embryo transfers as a mechanism is nec-
essary to reduce the risk of preterm birth  [209, 288] .
 5 Local and WHO guidelines should be followed.
 Advanced Maternal Age 
 • Rationale 
 Advanced reproductive age, commonly defined as ma-
ternal age of 35 years or older, is a risk factor for fetal 
chromosomal abnormalities as well as medical complica-
tions  [274] . Advanced maternal age, compared with ma-
ternal age under 35, is associated with worse pregnancy 
outcomes and maternal morbidity, with a higher inci-
dence of GDM, gestational hypertension, and preterm la-
bor  [296] . Pregnancies resulting from ART conferred fur-
ther additional risk with advancing maternal age  [297] . 
Older women are more prone to developing chronic ill-
nesses, particularly obesity, hypertension, and diabetes 
mellitus, although preexisting disease does not fully ex-
plain all the adverse events associated with age and ob-
stetric outcomes  [298] . Physiologic changes in pregnancy 
challenge aging organ systems that might be well com-
pensated in a nonpregnant state but may ultimately be 
overwhelmed by the increases in blood volume, cardiac 
output, and insulin resistance that accompany pregnan-
cy.
 • Recommendations for action 
 1 Women over 35 years should be counselled concern-
ing the increased risk of infertility, miscarriage, fetal 
anomalies, obstetric complications, and preterm birth 
and should know that their pregnancy is considered 
“high risk” due to their age.
 2 Local and WHO guidelines should be followed.
 Recommendation 2: On Fetal Exposure to Maternal 
Diabetes and Obesity 
 • Rationale 
 Hyperglycemia is one of the most common medical 
conditions women encounter during pregnancy. The 
prevalence of diabetes during pregnancy varies widely, 
but it is estimated that globally 17% of pregnancies are 
complicated by hyperglycemia  [96, 98] . Concerningly, in 
LMIC, around one half of women with hyperglycemia in 
pregnancy are undiagnosed. Around one sixth of hyper-
glycemia in pregnancy may be due to preexisting diabe-
tes, the prevalence of which appears similar across the 
globe, around 2% between ages 20 and 24 years and rising 
to 4% between ages 30 and 34 years  [98] . GDM, however, 
contributes the major portion of hyperglycemia in preg-
nancy, and the prevalence varies widely across the globe, 
in part due to varying diagnostic thresholds but also in 
part due to variability in the prevalence of maternal obe-
sity in pregnancy, advancing maternal age, and weight 
gain in pregnancy  [1, 299] . In LMIC, the rates vary with 
reports ranging from 0.4% in a cohort in Brazil to 24.3% 
in a cohort in Vietnam when defined by WHO criteria 
 [96] ( Table 9 ). Screening for GDM is not universal, and, 
therefore, the generalizability of these data is uncertain. 
GDM is associated with a higher incidence of maternal 
morbidity including cesarean deliveries, shoulder dysto-
cia, birth trauma, hypertensive disorders of pregnancy 
(including preeclampsia), and subsequent development 
of type 2 diabetes  [299, 300] . Perinatal and neonatal mor-
bidities also increase; the latter include macrosomia, birth 
injury, hypoglycemia, polycythemia, and hyperbilirubi-
nemia  [299, 300] . Exposure to hyperglycemia in early 
pregnancy has also been associated with IUGR  [300] . Ma-
ternal and neonatal mortality are also increased  [299] . In 
2013, it was estimated that 21.4 million live births were 
exposed to hyperglycemia during gestation  [299] .
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 Macrosomia is a major complication of both hyper-
glycemia in pregnancy and elevated maternal BMI  [18] . 
Increasing maternal age has also been found to be a risk 
factor  [18] . In developed countries, macrosomia occurs 
in 5–20% of pregnancies, but the incidence is increasing 
 [18] . In 23 developing countries, the incidence of macro-
somia (defined as a birth weight >4.0 kg) ranged from 
0.5% in India to 14.9% in Algeria  [18] . Long-term sequel-
ae in offspring with in utero exposure to maternal hyper-
glycemia and/or HBW include higher risk for obesity and 
diabetes later in life as well as renal disease  [26, 28, 39, 300, 
301] . Dietary counseling for diabetes and interventions to 
prevent GDM in pregnancy were found in randomized 
controlled trials to reduce the RR of having large for ges-
tational age (LGA) infants by 0.37 (95% CI, 0.20–0.66) 
and 0.09 (95% CI, 0.01–0.69)  [107] .
 In 2008, around 70% of adult American and Caribbean 
women were either overweight or obese, as were around 
40% of adult women in Africa  [103] . Women who gain 
excess weight in pregnancy tend to retain some of the 
weight gained with each pregnancy  [302] . A recent meta-
analysis found that, compared with women who gain the 
recommended amount of weight during pregnancy, those 
with a gestational weight gain above the recommenda-
tions retained, on average, an additional 3.06 kg after 3 
years and 4.72 kg 15 years postpartum  [303] . Close mon-
itoring of weight gain during pregnancy is important, es-
pecially in women who begin pregnancy overweight  [3] , 
not only to improve maternal health in the current preg-
nancy but also to prevent future maternal obesity.
 Maternal obesity is a growing problem worldwide,
including low-income countries  [97] . Recent data from 
sub-Saharan Africa showed that 19.1% of mothers were 
overweight and 5.3% were obese  [97, 284] . Importantly, 
women who were born LBW themselves but became 
obese have an increased risk of preterm birth compared 
to women who are just obese, illustrating the intergen-
eration impact of developmental programming  [126] . 
Maternal obesity is a strong risk factor for GDM, which 
increases with increasing maternal weight (OR 2.14, 95% 
CI, 1.82–2.53 for overweight; OR 3.56, 95% CI, 3.05–4.21 
for obese; OR 8.56, 95% CI, 5.07–16.04 for severely obese) 
compared with normal-weight mothers  [304] . Over-
weight or obesity in pregnancy are also associated with 
many adverse obstetric and perinatal outcomes, such as 
hypertension, preeclampsia, a higher incidence of cesar-
ean deliveries, preterm birth, macrosomia, and perinatal 
mortality  [97, 103, 303] . Women who were obese and ex-
perienced GDM have an increased risk of later-life diabe-
tes and CVD. Offspring of obese mothers have increased 
long-term risks of obesity, diabetes, and CVD  [305] . In-
terestingly, in a population level study of Caucasian and 
First-Nation Canadians with 24 years of follow-up, initia-
tion of breastfeeding prior to hospital discharge was as-
sociated with a significant reduction in the risk of subse-
quent maternal diabetes in both mothers who had and 
not had GDM  [306] . Similarly, the incidence of youth-
onset type 2 diabetes was reduced by 17% in breastfed 
offspring, demonstrating the importance of breastfeeding 
and the programming impact of good early nutrition 
 [306] . The mechanisms underlying these observations are 
unknown, but changes in insulin sensitivity, risk of obe-
sity, gut microbiome, and maternal and infant metabo-
lism have been suggested  [306] .
 • Recommendations for action 
 1 All pregnant women should be screened for hypergly-
cemia during pregnancy, and all countries should pro-
mote strategies to ensure this  [279] .
 (i) The WHO criteria for the diagnosis of diabetes
mellitus in pregnancy  [307] and the WHO and the In-
ternational Association of Diabetes in Pregnancy 
Study Group criteria for diagnosis of GDM  [307, 308] 
should be used when possible.
 (ii) Given resource constraints in many low-income 
countries, alternative strategies should also be consid-
ered, which are equally acceptable  [301] . They include 
at least the possibility to measure glucose in the urine 
to identify the presence of glycosuria as a risk factor for 
the subsequent detection of gestational diabetes.
 2 GDM should be managed in accordance with the avail-
able national guidelines  [309] . Achieve normoglyce-
mia with avoidance of hypoglycemia through preg-
nancy  [277, 279] .
 3 Nutritional counseling and physical activity should be 
the primary tools for managing GDM, which should 
be practical, affordable, and empower pregnant wom-
en to choose the right quantity and quality of food and 
level of physical activity.
 4 If lifestyle modification alone fails to achieve glucose 
control, metformin, glyburide, or insulin are safe and 
effective treatment options for gestational diabetes.
 5 Most normal gestational weight gain occurs after 20 
weeks of gestation, and the definition of “normal” is 
subject to regional variations but should take prepreg-
nant BMI into consideration. Women who are under-
weight at the start of pregnancy (i.e. BMI <18.5) should 
aim to gain 12.5–18 kg, women who are normal weight 
at the start of pregnancy (i.e., BMI 18.5–24.9) should 
aim to gain 11.5–16 kg, overweight women (i.e., BMI 
25–29.9) should aim to gain 7–11.5 kg, and obese 
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women (i.e., BMI >30) should aim to gain 5–9 kg  [3, 
310, 311] .
 6 Women should be counseled repeatedly during preg-
nancy to continue the same healthy lifestyle after de-
livery to reduce the risk of future obesity, type 2 diabe-
tes, CVD, and renal diseases  [276] .
 7 GDM should be documented in the mother’s and in-
fant’s health record.
 8 Breastfeeding should be initiated before hospital dis-
charge, as this is associated with a reduced risk of in-
cident diabetes in mother and offspring  [306] .
 9 Following a pregnancy complicated by GDM, the 
postpartum period is an important time to introduce 
beneficial health practices for both mother and child 
to reduce the future burden of several NCD.
 10 Obstetricians should establish links with family physi-
cians, internists, pediatricians, and other health care 
providers to support postpartum follow-up of gesta-
tional diabetic mothers and their children.
 11 A follow-up program linked to the child’s vaccination 
and regular health checkup visits provide an opportu-
nity for continued engagement with the high-risk 
mother-child pair.
 Recommendation 3: On Maternal Nutrition Early in 
and during Pregnancy 
 • Rationale 
 Pregnancy is a period of increased nutritional needs 
due to both the mother’s adaptation to pregnancy and to 
fetal and placental demands. Health outcomes associated 
with maternal nutrition range from infertility, miscar-
riage, fetal malformations, pregnancy diseases related to 
inadequate placental adaptation, such as IUGR, and pre-
eclampsia to gestational diabetes  [107, 312, 313] . Imbal-
ances in both nutritional intake and status during preg-
nancy may have long-lasting effects both on maternal 
health outcomes and the long-term health and develop-
ment of offspring through fetal programming of chronic 
diseases such as kidney diseases  [314] .
 Maternal undernutrition (defined as a BMI <18) is still 
prevalent worldwide, being most severe in South Asia 
where up to 40% of women are undernourished, which 
contributes to 25–50% of IUGR in the region  [103, 208] . 
South Asia also has the highest incidence of LBW glob-
ally at 28%  [3] . Short maternal stature (defined as height 
<155 cm) is a marker of chronic malnutrition in women 
and may also result from remaining stunted after been 
born LBW, preterm, or SGA  [105] . It has been estimated 
that maternal short stature is associated with 6.5 million 
SGA and/or preterm birth annually in LMIC  [104] . Im-
portant barriers to adequate maternal nutrition include 
female illiteracy, poverty, and gender inequality  [208] . 
Malnutrition during pregnancy ranges from total calorie 
inadequacy to micronutrient deficiencies, which may be 
acute or chronic and exacerbated by intercurrent illness, 
infection, stressfull work conditions, and environmental 
factors  [208] . Importantly, even obese mothers are at risk 
of micronutrient deficiency, which can have important 
programming effects  [3, 210] . WHO surveys conducted 
between 1993 and 2005 found anemia to be present in up 
to 40% of pregnant women, of which half was due to iron 
deficiency  [103, 208] . Iron supplementation in pregnancy 
has been associated with a 19% decrease in LBW  [107] . 
WHO data from 2006 estimated around 9.8 million wom-
en were vitamin A deficient in pregnancy, placing their 
offspring at risk for reduced nephron numbers  [208] . 
Some micronutrients, e.g., vitamin A, may be harmful if 
supplemented at high doses, and, therefore, supplemen-
tation is not routinely recommended, but a recent Co-
chrane review concluded that multiple-micronutrient 
supplementation with iron and folic acid is likely benefi-
cial  [310, 315] . Multiple-micronutrient supplementation 
of maternal nutrition with iron and folic acid compared 
to iron and/or folic acid in LMIC resulted in a reduced 
risk of LBW (RR 0.88; 95% CI, 0.85–0.90) and SGA (RR 
0.91; 95% CI, 0.74–0.97), although no effect was seen on 
preterm birth  [315] . Routine use of multiple-micronutri-
ent preparations is not, however, recommended in the 
latest WHO Antenatal Care Guidelines, as there may be 
some risk that has not yet been fully determined. The
current recommendations are, therefore, that pregnant 
women receive combined iron and folate supplementa-
tion as an effective means to reduce LBW and SGA  [310] .
 Healthy (traditionally based) dietary patterns during 
pregnancy, such as the New Nordic Diet  [316] and Med-
iterranean diets  [317] , are associated with a lower risk of 
having an SGA infant, while a potential causal link be-
tween maternal consumption of “junk food” and having 
a large newborn has been identified  [318] . The degree of 
Mediterranean diet adherence was positively associated 
not only with fetal size, but also with plasma folate and 
serum vitamin B 12 concentrations, and inversely corre-
lated with uteroplacental vascular resistance, plasma ho-
mocysteine, and high-sensitivity C-reactive protein levels 
 [317] . Inverse relationships were also reported between 
adherence to the Mediterranean diet  [319] , and Prudent 
and Traditional diets  [320] , and preterm delivery risk. 
The consumption of specific food item(s)/substances, 
such as fulfilling the fish intake criteria, resulted in a low-
er risk of preterm delivery  [320] , consistent with a meta-
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analysis indicating that never consuming fish in pregnan-
cy could be an extremely strong risk factor  [321] .
 The importance of all components of the maternal diet 
before and during pregnancy are reviewed in the recent 
WHO publication “Good Maternal Nutrition. The Best 
Start in Life”  [3] . The benefits of multiple nutrition sup-
plementation strategies which have the potential to im-
pact developmental programming in the kidney are high-
lighted in  Table 10 .
 Effectively addressing maternal and fetal nutrition re-
quires a life course and multisectoral approach, including 
agriculture, education, and social safety nets  [330] .
 • Recommendations for action 
 1 Maternal nutrition during pregnancy should be evalu-
ated carefully for the correct relationship between the 
quality of food intake and the characteristics of the 
mother, and for gestational weight gain.
 2 Appropriate maternal nutrition should consider in-
take not only of macronutrients (e.g., proteins, carbo-
hydrates, and fats) but also of micronutrients (e.g., 
iron, folate, and iodine), for which it may be easier to 
incur deficiencies or inadequacies  [3, 99, 310] . Impor-
tantly, obese women may have important nutritional 
deficiencies  [3] .
 3 Efforts should be made to ensure women start preg-
nancy with an appropriate nutritional status, with a 
healthy and balanced diet, and to keep gestational 
weight gain within the recommended ranges. mHealth 
applications have been shown to be effective in achiev-
ing this  [331] .
 4 Healthy dietary patterns (in particular the Mediterra-
nean diet) and micronutrient supplementation, par-
ticularly during the periconception period, as well as 
throughout pregnancy, should be encouraged, al-
though nutritional recommendations should remain 
culturally sensitive.
 5 Efforts to improve nutrition of women and girls re-
quire advocacy for a multisectoral approach, consis-
tent with the SDGs to reduce poverty, improve nutri-
tion, increase gender equality, education for girls, ac-
cess to family planning, reduce teenage pregnancy, 
and access to antenatal care  [4] .
 Recommendation 4: On Maternal Consumption of 
Tobacco and Alcohol and Caffeine Intake 
 • Rationale 
 Alcohol and tobacco exposure during development af-
fect the expression of genes involved in cell cycle control, 
apoptosis, and transcriptional regulation, mostly through 
epigenetic mechanisms  [332, 333] . Alcohol, tobacco, and 
caffeine exposure are associated with adverse maternal and 
child health outcomes  [269] . Such consumptions are mod-
ifiable risk factors for LBW and preterm birth, and, there-
fore, they are important targets for prevention strategies.
 Table 10.  Impact of nutritional interventions on birth weight and preterm birth and programming of blood pressure and kidney disease 
[103, 107, 315, 322–329]
LBW/
SGA
Prema-
turity
Preeclampsia/
eclampsia
HBW/
LGA
Child blood 
pressure
Child 
GFR
Child micro-
albuminuria
Iron and folate supplementation ↓ ↓ ↓ ↑
Micronutrient supplementation ↓ ↑↓1
Calcium supplementation ↓ ↓ ↓
Protein supplementation ↓ No effect
Vitamin A supplementation No effect Possible ↓
Folate supplementation ↓
Zinc supplementation ↓ No effect
Iodine supplementation ↓
Malaria prevention and treatment ↓
Treatment of genital infections ↓ ↓
Treatment of asymptomatic bacteriuria ↓
Magnesium sulfate ↓
Antiplatelet agents ↓ ↓ ↓
Diabetes education ↓
Smoking cessation ↓ ↓
1 No effect vs. iron/folate.
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 Alcohol. Alcohol is a toxic substance during pregnancy, 
particularly due to its teratogenicity  [334–338] . There are 
no safe limits for alcohol consumption in pregnancy  [339] . 
The first weeks of pregnancy are the most vulnerable to 
teratogenicity; however, risks have also been reported in 
the second and the third trimester, particularly for preterm 
deliveries and LBW  [340] , as well as for abnormal cogni-
tive development  [341] . Maternal alcohol consumption 
prior to, or during pregnancy, is associated with dose-de-
pendently increased risks of preterm birth and offspring 
LBW and SGA  [109, 342] . Interventions to reduce mater-
nal alcohol consumption during pregnancy were associ-
ated with a 202.1 g (95% CI, 60.85–343.35) increase in off-
spring birth weight [Appendix in  107 ]. Renal hypoplasia 
has been reported in association with fetal alcohol syn-
drome  [113] , and, in animals, acute prenatal alcohol expo-
sure was associated with reduced nephron numbers and 
subsequently increased blood pressure levels  [343] . The 
long-term consequences in humans require more study.
 Tobacco.  Both active and passive smoking prior to 
conception and during pregnancy are associated with ad-
verse reproductive outcomes, ranging from delayed con-
ception to spontaneous abortion and reduced birth 
weight  [344–346] . Dose-dependent effects have been 
demonstrated, with both maternal and paternal exposure 
associated with infertility and the risk of spontaneous 
abortion  [344] . LBW and preterm birth have been strong-
ly associated with smoking during pregnancy, particular-
ly during the third trimester  [347] . The relationship be-
tween smoking, birth weight, and preterm birth is subject 
to many confounders, but the strength of the associations 
is significant and therefore likely valid  [347] . Offspring of 
women smoking over 10 cigarettes per day weigh approx-
imately 200 g less at birth than offspring of nonsmokers, 
and the risk of preterm birth is increased by around 25% 
in smokers  [347] . These risks are likely related to chronic 
fetal hypoxemia, potentially due to both nicotine levels 
decreasing uterine vascularization and increased carbon 
monoxide transferred to the fetal circulation. In a popu-
lation-based study among women who had a previous 
preterm delivery, smoking was found to be a risk factor 
for subsequent moderate or very preterm delivery, al-
though this risk was eliminated if women stopped smok-
ing  [110] . Nicotine replacement strategies have been 
found to reduce preterm birth (RR 0.7; 95% CI, 0.61–
0.97); introduction of incentives to stop smoking were 
associated with a reduced risk of LBW (RR 0.45; 95% CI, 
0.22–0.93) [Appendix in  107 ]. The impact of nicotine re-
placement strategies on fetal and longer-term outcomes 
requires further study.
 It is estimated that although smoking rates have de-
clined in many developed countries over the past decades, 
11–13% of women still smoke throughout their pregnan-
cies and around 22–30% of nonsmoking women are pas-
sively exposed to smoke  [347] . In LMIC, smoking rates 
are increasing with a recently reported pool prevalence of 
2.6%  [348] . Smoking and exposure to passive smoke dur-
ing pregnancy are modifiable, and it has been estimated 
that combined current tobacco control policies and an 
increase in cigarette tax could prevent 227,300 LBW 
births and 351,100 preterm births between 2015 and 2065 
 [349] .
 In mice, exposure to maternal smoking was associ-
ated with reduced birth weights and spontaneous devel-
opment of albuminuria at 13 weeks of age  [350] . These 
findings were associated with evidence of increased ox-
idative stress and changes in mitochondrial structure 
and function in offspring kidneys  [350] . Similarly, in 
rats exposed to maternal smoking, birth weights and 
nephron numbers were reduced, proinflammatory pro-
teins were upregulated in offspring kidneys, and albu-
minuria and blood pressure increased over time  [111, 
351] . A prospective cohort study found that exposure to 
maternal smoking during pregnancy was associated 
with a dose-dependent reduction in fetal and infant kid-
ney volumes after adjustment for multiple variables, 
suggesting an independent impact of smoking on fetal 
kidney development  [114, 352] . In children studied at a 
mean age of 6 years, continued maternal smoking dur-
ing pregnancy was associated with a dose-dependent 
decrease in kidney volumes and estimated GFR  [114] . 
Albumin/creatinine ratios were increased among chil-
dren exposed to smoking during the first trimester 
 [114] . Importantly, among those whose fathers, but not 
mothers, smoked during pregnancy, renal volumes 
were also reduced, suggesting that even intermittent 
and environmental exposure to tobacco impacts kidney 
development  [114] . Exposure to maternal smoking dur-
ing gestation is also associated with an increased risk of 
gestational diabetes in daughters, which may contrib-
ute to the intergenerational impact of programming 
through smoking  [353] .
 Caffeine. Caffeine intake was consistently associated 
with a lower birth weight and higher odds of SGA, not 
only when consumption exceeds the WHO recommen-
dation (300 mg/day)  [310] , but even with the intake rec-
ommended in Nordic countries and the USA (maximum 
200 mg/day)  [108] ,  which suggests a risk of SGA even at 
very low caffeine intake levels.
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 • Recommendations for action 
 1 Pregnant women should be asked about alcohol and 
tobacco use. Tobacco and alcohol should not be used 
in pregnancy  [109, 342] .
 2 Women should be advised that both alcohol and to-
bacco may also have an impact on the gametes in the 
periconception phase, so women planning pregnancy 
should avoid alcohol and tobacco.
 3 Tobacco control policies should be implemented and 
impact monitored to determine cost and effectiveness 
of strategies in local contexts.
 4 Exposure to passive smoke during pregnancy should 
be avoided; therefore, women should be asked and ed-
ucated about household or occupational smoke expo-
sure.
 5 Smoking reduction efforts must be directed at house-
hold members of pregnant women as well as the preg-
nant woman herself.
 6 Offspring of mothers who used alcohol or smoked 
during pregnancy should be followed long term.
 7 Women should be advised to reduce coffee intake to a 
minimum  [310] .
 Recommendation 5: On Screening, Risk Factors, 
Detection, and Monitoring of Hypertensive Disorders 
in Pregnancy 
 • Rationale 
 A recent systematic review including 39 million wom-
en from 40 countries estimated that 4.6 and 1.4% of preg-
nancies were affected by preeclampsia and eclampsia be-
tween 2002 and 2010, respectively, although most studies 
included came from North America and Europe  [354] . A 
subsequent cross-sectional study of 357 higher-volume 
health facilities across 29 LMIC found that 2.73% of 
women had hypertensive disorders during pregnancy: 
2.16% had preeclampsia, 0.28% eclampsia, and 0.29% 
chronic hypertension  [355] . Preeclampsia increases the 
risk of LBW and preterm birth, and is associated with 
higher childhood and young adult blood pressures in off-
spring  [77, 355, 356] . In prior decades, it has been esti-
mated that 12% of SGA infants and 20% of those born 
preterm result from preeclampsia  [357] . Women born 
with LBW or SGA themselves are at increased risk of 
pregnancy-induced hypertension in their own pregnan-
cies  [358] . Women who were born with SGA (<5th per-
centile  z -score) were 2- to 3-fold more likely to have pre-
eclampsia before 34 weeks of gestation compared with 
those with birth weights between the 25th and 75th per-
centiles  [359] . Women who develop preeclampsia are 
more likely to have high blood pressure and dyslipidemia 
several years before pregnancy, factors which may be as-
sociated with the women themselves having been born 
with LBW  [360] . From a cross-sectional study including 
313,030 women from 29 countries, maternal renal disease 
(OR 4.52; 95% CI, 3.63–4.54) and chronic hypertension 
(OR 8.32; 95% CI, 7.13–9.72) were most strongly associ-
ated with the odds of preeclampsia, and these odds in-
creased 1.5- to 2-fold for eclampsia. Preexisting maternal 
diabetes is associated with an RR for preeclampsia of 3.56 
(95% CI, 2.54–4.99)  [361] . Consistent with either a pro-
grammed or genetic risk, previous preeclampsia, espe-
cially early in gestation, increases the risk of developing 
preeclampsia in later pregnancies  [362, 363] . Women 
who experience preeclampsia have a 2-fold increased risk 
of long-term CVD and an approximately 10-fold in-
creased risk of ESKD  [204, 364–366] . Indeed, many stud-
ies in women with previous preeclampsia, but not all, 
have shown an increased risk of developing hypertension 
later in life and increased mean blood pressure compared 
to women without preeclampsia  [367–369] . Further-
more, 2 meta-analyses have shown a greater than 2-fold 
increased risk of ischemic heart disease/cardiac disease 
later in life, and an increased risk of later hypertension, 
stroke, and venous thromboembolism, but no significant 
association with peripheral arteriosclerosis  [364, 370] 
( Table 11 ).
 Several studies have also found an association between 
preeclampsia and future kidney disease  [204, 365, 371] 
( Table 11 ). A recent meta-analysis of 7 studies showed 
that microalbuminuria was present in 31% of women 7 
years after a preeclamptic pregnancy  [365, 373, 374] . In a 
thoroughly performed Norwegian study of otherwise 
healthy women, preeclampsia 10 years earlier was not as-
sociated with an increased risk of persisting microalbu-
minuria, suggesting lower absolute risks than anticipated 
in otherwise healthy women  [375] .
 A recent study from the US also suggested a possible 
modulation of the association of preeclampsia with later-
life ESKD by obesity  [376] . Effective screening for early 
detection and management of cardiovascular and renal 
risk factors may, therefore, have an important impact on 
long-term morbidity in these women.
 Major challenges remain to determine the risk of pre-
eclampsia in the individual patient and to detect it early 
and manage it optimally to safely delay delivery and im-
prove maternal and fetal outcomes. For example, the use 
of antihypertensives for moderate maternal hypertension 
has not been associated with reductions in the rates of 
preterm birth or infant SGA [Appendix in  107 ]. The use 
of antiplatelet agents in women at risk of preeclampsia, 
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however, was associated with risk reductions in pre-
eclampsia (RR 0.83; 95% CI, 0.77–0.89), preterm birth 
(RR 0.92; 95% CI, 0.88–0.97), and SGA (RR 0.90; 95% CI, 
0.83–0.98) [Appendix in  107 ]. Supplementation of calci-
um during pregnancy in populations with low calcium 
intake, before 20–32 weeks of gestation and continued 
until delivery, was also associated with risk reductions in 
preeclampsia (RR 0.48; 95% CI, 0.34–0.67) and severe 
preeclampsia (RR 0.75; 95% CI, 0.57–0.98), as well as ges-
tational hypertension (RR 0.65; 95% CI, 0.53–0.81) [Ap-
pendix in  107 ;  310 ].
 • Recommendations for action 
 1 Women at increased risk of preeclampsia (including 
hypertension, renal disease, diabetes, obesity, prior 
preeclampsia, advanced maternal age, or having them-
selves been LBW, SGA, or preterm) should undergo 
preconception care to optimize any modifiable risk 
factors or conditions.
 2 National guidelines adopted for the prevention and 
treatment of preeclampsia should be followed  [377] .
 3 All women should be screened for hypertensive disor-
ders of pregnancy at regular antenatal clinic visits 
starting from 20 weeks of gestation for prompt treat-
ment and close follow-up. Simple screening is possible 
in communities if community health workers are ad-
equately trained. There are promising new biomarkers 
(s-Flt, endoglin, and platelet-derived growth factor) 
that could be used as screening tools where available 
 [378, 379] .
 4 Early detection of hypertensive disorders of pregnancy 
 can enable appropriate antihypertensive treatment, 
lifestyle modification, and close monitoring of mater-
nal and fetal health. National guidelines adopted for 
hypertensive disorders of pregnancy should be fol-
lowed.
 5 A possible tool to diagnose/monitor hypertensive dis-
orders could be the presence of an abnormal Doppler 
waveform in the uterine arteries which has been ac-
cepted as a sign of severity of preeclampsia and a sign 
that might predict the appearance of hypertensive dis-
orders in pregnancy when found in asymptomatic pa-
tients. However, the positive predictive value might 
change according to the population screened (50/70%) 
 [380] .
 6 Given the lack of specific therapy to treat preeclampsia 
or eclampsia when floridly manifest, close monitoring 
of the mother and fetus could permit timely interven-
tions to maximize the safety and survival of both  [361] .
 7 Women who experience preeclampsia/eclampsia 
should receive life-long screening and follow-up for 
CVD and renal disease and receive immediate lifestyle 
education.
 Recommendation 6: On Fetal Growth (Detection, 
Management, and Possible Interventions) 
 • Rationale 
 The strict definition of being SGA is an infant that is 
born under the 10% of birth weight for gestational age in 
 Table 11.  Maternal long-term risks after adverse pregnancy outcomes
Clinical event Maternal outcome1 Relative risk (95% CI) Reference
Preeclampsia Hypertension 3.7 (2.7 – 5.05) 364
Cardiovascular disease 2.16 (1.86 – 2.52) 364
Stroke 1.81 (1.45 – 2.27) 364
Death 1.49 (1.05 – 2.14) 364
Microalbuminuria 4- to 8-fold increase 365
End-stage renal disease 4.7 (3.6 – 6.1)2 204
Kidney biopsy 3.3 (2.5 – 4.2)2 371
LBW infant End-stage renal disease 2.7 (1.8 – 3.8)2 204
Kidney biopsy 2.0 (1.5 – 2.7)2 371
LBW + preeclampsia End-stage renal disease 6.8 (3.9 – 12.0) 204
Kidney biopsy 4.8 (2.8 – 8.2)2 371
Preterm birth End-stage renal disease 3.8 (2.9 – 4.9) 204
Gestational diabetes Diabetes type 2 7.43 (4.79 – 11.51) 372
 LBW, low birth weight.
1 Follow-up times vary, see individual studies. 
2 1st pregnancy; see references for risks with more pregnancies/episodes of preeclampsia.
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a population  [20] . Growth restriction may, however, be 
more subtle and is often overlooked, although it remains 
highly relevant in developmental programming. It is not 
possible to predict what the birth weight of each infant 
should be, but tracking an individual infant’s growth rate 
through pregnancy would permit detection of a slowing 
growth rate as a signal for growth restriction and may 
prompt intervention. Such growth would most accurate-
ly be monitored through repeated ultrasound, but evalu-
ation of fundal height in low-resource regions is very
useful.
 Fetal growth standards have recently been published 
 [381, 382] , but there is much discussion whether these 
standards should be customized for ethnicity, maternal 
features, and parity  [383, 384] . Indeed, it has been shown 
that customized standards are more reliable than popula-
tion standards in predicting adverse outcomes of SGA fe-
tuses  [385] . There is, however, no consensus regarding 
the role of ultrasound in the evaluation of fetal growth in 
the third trimester and even at what exact gestational age 
this should be conducted in low-risk pregnancies  [386, 
387] . The best parameter identified for the assessment of 
growth is measuring abdominal circumference, and, ac-
cording to recent publications, the gestational age with 
the highest predictive value is between 34 and 36 weeks 
 [388] . Furthermore, the evaluation of Doppler velocim-
etry of uterine, umbilical, and cerebral arteries, as well as 
the ductus venosus, can improve monitoring of fetal 
growth and planning timing of delivery  [389] . An assess-
ment of fetal size could at least flag the fetus/pregnancy 
as high risk early on, and appropriate arrangements can 
be made for the safest possible delivery and maximal sup-
port for the baby, if available. A recent study, for example, 
described maternal work conditions during pregnancy as 
a risk factor for LBW  [390] . Therefore, some conditions 
could be modified to improve outcomes.
 Strategies that have been found beneficial for the pre-
vention of SGA include: multiple micronutrient supple-
mentation (RR 0.87; 95% CI, 0.83–0.92), balanced energy 
protein supplementation (RR 0.68; 95% CI, 0.49–0.89), 
intermittent preventive therapy for malaria in pregnancy 
(RR 0.65; 95% CI, 0.55–0.77), use of insecticide-treated 
bed nets (RR 0.65; 95% CI, 0.55–0.77), and antiplatelet 
agents for preeclampsia (RR 0.90; 95% CI, 0.83–0.98) 
[Appendix in  107 ]. No intervention has yet been success-
ful in improving growth when growth restriction is de-
tected, although maternal rest, treatment of hyperten-
sion, and maternal anemia may improve growth restric-
tion  [391] . Depending on gestational age, one strategy is 
to try to postpone delivery in order to improve fetal ma-
turity, until it shows a good capacity for adaptation. This 
approach has been studied extensively for early severe 
growth restriction  [392] . There is no consensus regarding 
when to deliver growth-restricted babies detected late in 
the third trimester.
 • Recommendations for action 
 1 Growth restriction can be prevented or reduced 
through good maternal nutrition, antibiotic treatment 
of asymptomatic bacteriuria, and prompt treatment of 
malaria [Appendix in  107;  310 ].
 2 Monitoring fetal growth would enable early detection 
of fetal growth restriction. Measuring uterine size us-
ing fundal height should be part of the routine assess-
ment of low-risk pregnant women according to local 
practice  [310] .
 3 All pregnant women with lower-than-expected uter-
ine size, as well as all women who are not at low risk, 
should undergo ultrasound evaluation of fetal growth 
and, where possible, Doppler velocimetry of uterine, 
umbilical, and cerebral arteries, and the ductus veno-
sus.
 4 Once growth restriction is detected, emphasize mater-
nal rest and treatment of hypertension and anemia.
 5 In growth-restricted fetuses, the best timing for deliv-
ery in order to avoid in utero fetal acidosis can be iden-
tified by using cardiotocography and fetal Doppler ve-
locimetry  [393] .
 Recommendation 7: On the Detection and 
Documentation of Birth Weight and Gestational Age 
 • Rationale 
 LBW has been defined by the WHO as weight at birth 
of less than 2.5 kg  [20, 34] ( Table 1 ). VLBW is defined as 
less than 1.5 kg, extremely low birth weight (ELBW) as 
less than 1.0 kg. LGA is defined as a birth weight >2 stan-
dard deviations above the mean birth weight for gesta-
tional age, and macrosomia is defined as a birth weight 
above 4 or 4.5 kg. SGA is defined as a birth weight <10th 
percentile for gestational age or <2 standard deviations 
below the mean birth weight for gestational age. IUGR 
reflects the failure of normal fetal growth. There is sig-
nificant overlap between preterm birth and LBW as in-
fants born at lower gestational ages are smaller than term 
infants  [28] ( Fig. 1 ). Preterm infants can either be born 
with a birth weight AGA or SGA. Importantly, growth 
restriction may be present in infants not meeting criteria 
for LBW or SGA; therefore, a clinical challenge exists 
how to identify such children who are also at risk of the 
effects of developmental programming. The WHO esti-
mated that in 2014 globally 15–20% of live births per year 
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are LBW, representing over 20 million infants  [34] . 
Global estimates of preterm birth in 2010 estimated that 
11.1% of all live births were preterm, representing around 
14.9 million babies  [33] . Using 22 birth cohort studies 
and the WHO Global Survey on Maternal Health and 
Perinatal Health (reflecting data from 138 LMIC), Lee
et al.  [28] estimated that in 2010, 32.4 million infants 
were born SGA representing 27% of live births ( Fig. 1 ; 
 Table 12 ).
 In this study, over 50% of term SGA babies weighed 
>2.5 kg; therefore, such infants may not be identified as 
having been growth restricted if LBW is the only param-
eter considered  [28] . The proportions of infants born 
with more subtle forms of growth restriction is unknown. 
Macrosomia at birth ranges from 5–20% in developed 
countries to 0.5–15% in developing countries  [18] . Many 
infants in LMIC are born at home and never weighed, 
and, therefore, the current rates may underestimate the 
true proportions of infants born LBW or preterm  [34] . 
Given the varying global distributions of birth weight and 
preterm birth  [34] ( Fig.  2 ), specific reference charts 
should be adapted for different populations to permit 
study of long-term associations with birth weight in local 
contexts and to increase accuracy in predicting the pro-
gramming risk in infants with LBW and SGA  [15] . While 
in industrialized countries the epidemiology of LBW has 
been extensively studied, in less-developed countries reli-
able data on LBW and its consequences remain limited 
 [394] .
 Initially attributed solely to IUGR and a deprived
fetal environment, the phenomenon of fetal program-
ming has been expanded to include preterm infants 
 [20] . Some authors have argued that preterm birth is the 
predominant risk factor, and others have argued that 
IUGR is the relevant factor. Evidence supports preterm 
birth, IUGR, and LBW as robust markers for intrauter-
ine programming of hypertension and renal disease, 
and, as shown in  Table 4 , hazard ratios for ESKD are 
highest when preterm birth and SGA coexist  [29] . HBW 
is also emerging as a risk factor for kidney disease and 
diabetes in later life. Such birth parameters must be doc-
umented to highlight an individual’s risk. It is impor-
tant to realize that the risk does not mean disease; it may 
be modified through good nutrition and weight control 
as well as screening and early management of blood 
pressure and proteinuria.
 Table 12.  Proportion of infants born LBW, AGA, SGA, preterm, or with macrosomia [18, 28, 33, 34]
Studies reporting the proportion of infants born LBW, AGA, SGA, preterm, or macrosomic
2010
138 LMIC [28]
WHO LBW 
policy brief [34]
2010, 
systematic analysis, 
184 countries [33]
data from the WHO global survey
on maternal and perinatal  health [18], 
% of total
n
(million)
% of total n
(million)
% of total n 
(million)
% of total developed
countries
developing
countries
Term (all) 106.6 88.6
Preterm (all)
Min
Max
13.7 11.4 14.9 
12.3
18.1
11.1 
9.1
13.4
Term AGA 77.0 64
LBW (all) 37.0 30.8 >20 15 – 20
SGA (all) 32.4 26.9
Term SGA
No LBW 19.0 15.8
LBW 10.6 8.8
Preterm AGA
No LBW 6.3 5.2
LBW 4.6 3.8
Preterm SGA with LBW 2.8 2.3
Macrosomia 5 – 20 0.5 – 14.9
 AGA, appropriate for gestational age; LBW, low birth weight; LMIC, low- and middle-income countries; SGA, small for gestational 
age; WHO, World Health Organization. 
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 • Recommendations for action 
 1 The WHO and UNICEF recommend that all infants 
be weighed at birth.
 Birth weight and gestational age at birth should be re-
corded on the newborn’s health record for use in mon-
itoring the infant’s growth and as part of the individu-
al’s lifetime health record.
 2 A birth weight <2.5 kg, gestational age <37 weeks, or 
an SGA or HBW birth should be documented and be-
come a prominent part of the person’s medical record.
 3 Such documentation could be encouraged in concert 
with the UN-SDG goal that each child should have a 
birth certificate.
 4 Better strategies are required to identify growth-re-
stricted infants that do not fall under the traditional 
categories of LBW, SGA, or preterm birth.
 Recommendation 8: On the Risk Factor of Preterm 
Birth 
 • Rationale  
 In 2010, it was estimated that around 14.9 million in-
fants were born preterm worldwide  [33] . In a cross-coun-
try analysis of high human development index countries, 
the cause of preterm birth remained unknown in up to 
two thirds of cases  [267] . Such data are not reported for 
LMIC, but it is known that over 60% of preterm babies 
globally are born in Asia and sub-Saharan Africa  [33] , 
possibly related to the high prevalence of maternal under-
nutrition in these regions  [208] . Known risk factors for 
preterm birth are multiple, including maternal diabetes, 
kidney disease, preeclampsia, infections, nutritional defi-
ciencies, and use of some medications  [143] . Many of 
these factors have been shown to reduce nephron num-
bers and kidney size, or increase blood pressure in ex-
perimental animals exposed during gestation  [15] . As 
60% of nephrons are formed during the third trimester, 
children born preterm have a significantly lower number 
of nephrons at birth, which do not catch up adequately 
postnatally  [395, 396] . Preterm birth itself, as well as 
many risk factors for preterm birth, may, therefore, have 
compounding effects on nephrogenesis in preterm in-
fants. In addition, preterm infants are at increased risk for 
AKI postnatally, which may further disrupt nephrogen-
esis. Progressive kidney disease in preterm individuals is 
multidimensional, with genetic and environmental events 
(hypoxia, hyperoxia, nephrotoxic drugs, hypotension, 
AKI, thrombosis, bleeding, free radical toxicity, and oth-
er injuries) contributing to disease risk  [15, 20, 137] .
 Successful strategies in women with prior preterm 
births have been estimated to reduce subsequent preterm 
birth in high-income countries by: cessation of smoking 
(10–20%), reducing multiple embryo transfers during 
ART (63%), cervical cerclage (20%), progesterone sup-
plementation (45%), avoidance of nonmedically indicat-
ed cesarean section (55%), and close follow-up in preterm 
birth prevention clinics (13%)  [209, 288] . Many of these 
interventions are easily accessible in LMIC. Other strate-
gies that have proven beneficial include: calcium supple-
mentation (RR 0.76; 95% CI, 0.60–0.97), syphilis screen-
ing and treatment (RR 0.36; 95% CI, 0.27–0.47), screen-
ing and treatment of lower genital tract infections (RR 
0.55; 95% CI, 0.41–0.75); antiplatelet agents for pre-
eclampsia (RR 0.92; 95% CI, 0.88–0.97), and nicotine re-
placement therapy (RR 0.77; 95% CI, 0.61–0.97) [Appen-
dix in  107 ]. The use of prenatal antidepressants was found 
to increase the risk of preterm birth (RR 1.55; 95% CI, 
1.38–1.74) [Appendix in  107 ]. Optimization of maternal 
weight (avoidance of under- or overweight), reduction of 
maternal stress, and treatment of periodontal disease are 
also potential strategies to reduce preterm birth  [288] .
 • Recommendations for action 
 1 Women should be screened before conception or ear-
ly in pregnancy for known risks factors for preterm 
birth.
 2 Simple preventive strategies should be routinely im-
plemented (nutrition, prevention, and treatment of
infections).
 3 In women at high risk of preterm birth (especially 
those with a prior history of preterm birth), preventive 
strategies should be implemented if possible  [209] . 
Measurement of the length of the uterine cervix at 22–
24 weeks of gestation and prevention of vaginal infec-
tions should be considered.
 Recommendation 9: On Neonatal AKI and
Drug-Induced Renal Damage 
 • Rationale 
 AKI occurs in 16–70% of preterm infants  [136, 137] , 
40% of neonates with severe perinatal asphyxia, and 60% 
of newborns who undergo cardiopulmonary bypass for 
congenital heart disease  [138] . AKI is an important risk 
factor for death in neonates  [136, 138] . The risk factors 
for AKI include lower gestational age and birth weight, 
SGA, renal hypoperfusion, nephrotoxin exposure, sepsis, 
obstruction, and renal arterial or venous thrombosis 
 [142, 159] . Preterm and critically ill newborns are predis-
posed to developing AKI because of renal function im-
maturity and incomplete nephrogenesis in the early post-
natal period, which can be irreversibly impaired by drug 
exposure, and cellular injury to glomeruli or tubules, 
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which may impair repair capacity and increase suscep-
tibility to renal disease later in life  [147, 160] . The man-
agement of neonates in intensive care often requires a 
combination of various therapeutic agents, frequently 
unlicensed or off-label, with many of them potentially in-
ducing renal tissue injury  [397, 398] . Antibiotics (amino-
glycosides and vancomycin), antifungals (amphotericin 
B), antivirals (acyclovir), angiotensin-converting enzyme 
inhibitors, and NSAID can induce nephrotoxic damage 
through several concomitant mechanisms of action on 
different segments of the nephron and may directly im-
pair any ongoing nephrogenesis in a preterm infant  [136, 
141, 143, 146] . A retrospective review found that 87% of 
neonates in ICU were exposed to at least 1 nephrotoxic 
medication for an average duration of around 2 weeks 
 [141] . In this study, greater nephrotoxin exposure was as-
sociated with lower gestational age, lower birth weights, 
being SGA, and an increased risk of AKI  [141] .
 Serum creatinine levels are widely used in the diagno-
sis of AKI in adults and older children, but its utility in 
preterm infants is limited by maternal creatinine, imma-
ture renal tubule function, and, until recently, the lack of 
a clear definition of AKI  [136, 142, 399] . A neonatal AKI 
classification which should improve uniformity of diag-
nosis and comparability of data across institutions has 
recently been proposed  [136, 142, 147] ( Table 13 ).
 Identification of new biomarkers predicting nephro-
toxicity and enabling the early detection of AKI could
improve patient outcome  [139, 147, 400, 401] .
 Most of the discussion around neonatal AKI occurs in 
high-resource countries where preterm babies have an in-
creased chance of survival and access to ICU care. Little 
data exist from lower-income settings, where risks should 
be at least as high. One study from Kenya found 71% mor-
tality by 7 days among asphyxiated term neonates with 
AKI, although specific therapies available were not de-
scribed  [402] .
 Data from pediatric ICU patients have shown that 
about 10% will develop CKD 1–3 years after AKI  [163] . 
This burden may be higher in preterm infants, because of 
the reduced number of nephrons  [137, 165] , although this 
requires further study. A recent study from the US, where 
40% of ICU neonates experienced AKI, found that AKI 
was only recorded in the discharge summary in 13.5% of 
infants, and none were referred for nephrology follow-up 
 [159] . This study illustrated the lack of awareness of the 
potential long-term impact of neonatal AKI.
 • Recommendations for action 
 1 Preterm birth, LBW, and SGA must be recognized as 
risk factors for AKI.
 2 Every effort to prevent AKI should be made  [142, 403] :
 (i) Optimize fluid management in order to maintain 
circulating volume and to preserve blood pressure.
 (ii) Minimize use of nephrotoxins (antibiotics, anti-
fungals, antivirals, renin-angiotensin system inhibi-
tors, NSAID, and radiocontrast agents).
 (iii) Monitor aminoglycoside drug levels when pro-
longed treatment is necessary.
 (iv) Administer nephrotoxic drugs (if necessary) at the 
lowest effective dose while monitoring drug levels, flu-
id balance, and renal function.
 (v) With established nephrotoxicity, reassess the drug 
dose and avoid concomitant administration of more 
nephrotoxic drugs.
 (vi) Pay close attention to nutrition to optimize renal 
recovery.
 (vii) Consider renal ultrasound to assess congenital 
abnormalities and obstruction to enable timely correc-
tion.
 Table 13.  Neonatal AKI KDIGO classification [reprinted with permission from 136]
Stage Serum creatinine Urine output
0 No change in serum creatinine or rise <0.3 mg/dL ≥0.5 mL/kg/h
1 Serum creatinine rise ≥0.3 mg/dL within 48 h or serum creatinine rise 
≥1.5 – 1.9 × reference serum creatinine1 within 7 days
<0.5 mL/kg/h for 6 – 12 h
2 Serum creatinine rise ≥2.0 – 2.9 × reference serum creatinine1 <0.5 mL/kg/h for ≥12 h
3 Serum creatinine rise ≥3.0 × reference serum creatinine1 or 
serum creatinine ≥2.5 mg/dL2 or receipt of dialysis
<0.3 mL/kg/h for ≥24 h or anuria for ≥12 h
 Differences between the proposed neonatal AKI definition and KDIGO include the following: 
1 Reference serum creatinine will be defined as the lowest previous serum creatinine value. 
2 Serum creatinine value of 2.5 mg/dL represents <10 mL/min/1.73 m2.
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 3 AKI should be recognized early, and appropriate in-
terventions should be instituted to minimize renal in-
jury and optimize recovery.
 4 Episodes of neonatal AKI, even if mild, should be re-
ported to primary physicians upon discharge from 
hospitalization.
 5 Infants who experienced AKI, especially if preterm, 
LBW, or SGA infants, require life-long follow up of 
blood pressure and renal function.
 Recommendation 10: On Toxic Gestational 
Medication Exposure 
 • Rationale 
 The fetus and infant may be more vulnerable to toxic 
environmental exposure during the sensitive time of or-
gan development. Exposure to nephrotoxic agents during 
kidney development can result in a reduction in nephron 
number, as well as disruption of nephron structure and/
or function. Many medications that may impact kidney 
development, e.g., renin-angiotensin system inhibitors, 
are contraindicated in pregnancy; however, some medi-
cations, including gentamicin, penicillins, ceftriaxone, 
cyclosporine, long-term dexamethasone, nonsteroidal 
antibiotics, and COX-2 inhibitors, given during gestation 
have been found to reduce nephron number or result in 
abnormal nephron development in experimental animal 
offspring and, in some cases, to lead to renal dysfunction 
and higher blood pressures with age  [149, 404–411] . The 
impact of many of these medications on kidney devel-
opment in humans is unknown. Very small studies in 
children of mothers with organ transplants who were
exposed to cyclosporine in utero have not shown ab-
normalities in renal function or structure  [157, 412] . 
Short-term antenatal steroid exposure has not been asso-
ciated with an increase in blood pressure at age 2 or 30 
years  [413, 414] . Similarly, prenatal corticosteroids did 
not modify the association of blood pressure with renal 
function in preterm infants aged 12–36 months  [415] . 
Short-term perinatal steroid use, therefore, may not have 
a programming effect on the developing kidney; however, 
the effects of long-term steroid use remain to be studied. 
Maternal vitamin supplementation is important to re-
duce the risk of LBW and preterm birth, but excessive 
vitamin A supplementation may arrest nephrogenesis, 
and folate intake alone may be associated with an in-
creased risk of congenital renal anomalies  [416, 417] . Ma-
ternal exposure to the tocolytic nimesulide and other 
NSAID shortly before delivery has been associated with 
severe neonatal AKI and even ESKD  [156, 418–420] . The 
risks and benefits of medication use in pregnant women 
should be carefully considered. Screening and treatment 
of lower genital tract infections has been associated with 
reduced risks of preterm birth (RR 0.55; 95% CI, 0.41–
0.75) and LBW (RR 0.48; 95% CI, 0.34–0.66), and treat-
ment of asymptomatic bacteriuria was associated with a 
reduction in infant LBW (RR 0.66; 95% CI, 0.49–0.89) 
[Appendix in  107 ]. However, the choice of the antibiotic 
may affect nephrogenesis.
 • Recommendations for action 
 1 Nephrotoxic drugs should be avoided or used only if 
there are no alternatives.
 2 When used, nephrotoxic drugs should be adminis-
tered at the lowest effective dose while monitoring 
drug levels, fluid balance, and renal function.
 3 Long-term impact of maternal medication use on 
child and adult renal function requires further study.
 Recommendation 11: On Infant and Child Nutrition 
 • Rationale  
 Childhood undernutrition remains a global problem, 
with 156 million children under age 5 years in 2015 being 
stunted and 50 million being wasted  [421] . The majority 
of these children were from Asia and Africa. In contrast, 
during the same period, it was estimated that 42 million 
children under age 5 years were overweight, the majority 
of whom were from Asia and Africa  [103, 421] . Stunting 
is associated with having been born LBW, SGA, or pre-
term  [105] . Childhood stunting leads to short maternal 
stature and maternal underweight, which are risk factors 
for IUGR in pregnancy  [103, 208] , emphasizing the trans-
generational impact of early nutrition. Most stunting oc-
curs within the first 1,000 days after conception, and, 
therefore, optimizing nutrition during this period is cru-
cial  [103] . Weight gain during these first 1,000 days is also 
important in programming adult lean body mass  [103] . 
Weight gain after 1,000 days is associated with later life 
obesity  [103] . The timing and quality of postnatal and 
early childhood nutrition after LBW, SGA, or preterm 
birth are, therefore, important contributors to long-term 
risk of chronic diseases  [422] .
 In preterm infants and infants with IUGR, both over- 
and undernutrition at critical stages of development may 
have undesirable consequences: while growing quickly 
increases the risk of obesity, dyslipidemia, hypertension, 
and type 2 diabetes, slower weight gain velocity may delay 
mental performance. This double detrimental-beneficial 
effect of early feeding in this high-risk population has be-
come the neonatologist’s dilemma  [423] . Human milk is 
the optimal nutrient for term and preterm infants, but 
this may not meet the nutritional requirements of VLBW 
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and ELBW infants  [424] . Supplementation of human 
milk may be required, and, after hospital discharge, nu-
tritional prescriptions may need to be adjusted to main-
tain optimal growth rates and avoid obesity.
 In infancy, exclusive breastfeeding for 6 months has 
been recommended by the WHO because of its beneficial 
effects for preventing long-term NCD  [425] . Both breast-
feeding during the first months of life and avoiding rapid 
weight gain in childhood have been shown to prevent lat-
er risk of obesity  [426, 427] as well as dyslipidemia, hy-
pertension, and reduced glucose tolerance  [428] .  A high-
er protein content in infant formulas (than in breast milk) 
has been shown to increase weight gain velocity and kid-
ney growth during the first few months of life  [429] , as 
well as the later risk of becoming overweight  [31, 430] . In 
childhood and adolescence, the ingestion of a combina-
tion of sugars, salt, and fat and protein from red meat af-
fects multiple metabolic functions and is associated with 
a higher incidence of the metabolic syndrome  [431] , 
which increases the risk of developing CKD. In contrast, 
a prudent dietary pattern (reduced sodium, carbohy-
drates, and saturated fat) is beneficial, especially when 
combined with increased physical activity  [432] . Adher-
ence to a Mediterranean diet (plant foods, fresh fruits, 
fish, poultry, dairy products, and olive oil as the main 
source of fat) is associated with lower blood pressure, 
blood glucose, and triglycerides. Obesity contributes sig-
nificantly to the development and progression of CKD: 
hyperfiltration and hypertrophy occur in response to the 
increased metabolic needs of obesity  [433, 434] .
 Poverty is not the only contributor to childhood un-
dernutrition. A recent retrospective analysis of demo-
graphic and health surveys from 1990 to 2011 across 36 
LMIC found no association between the change in the 
per-capita gross domestic product over time and the aver-
age prevalence of child undernutrition  [435] . This study 
suggests that factors other than macro- or household eco-
nomic growth can impact childhood nutrition, further 
emphasizing the importance of a multisectoral approach 
to child health outlined by the SDG. Others have sug-
gested that investment in agriculture, social safety nets, 
child development, and parental education could all con-
tribute to improved maternal and child nutrition  [330] .
 • Recommendations for action 
 1 The recommended feeding for children is exclusive 
breastfeeding for the first 6 months of life and contin-
ued breastfeeding through the second year of life  [103, 
436] .
 2 Prudent introduction of other food sources should be 
done, enabling regular and balanced growth.
 3 Quality of nutrition in preterm VLBW and ELBW in-
fants must be closely monitored.
 4 Child weight and height should be regularly moni-
tored on appropriate growth charts, and any rapid up-
ward crossing of weight centiles, especially when dis-
proportionate to increases in height and even if still 
within the accepted range of centiles, must be noted, 
and appropriate nutrition and physical activity coun-
seling given to prevent obesity.
 5 In childhood and adolescence, a prudent dietary pat-
tern (reduced sodium, carbohydrates, and saturated 
fat), possibly adhering to the Mediterranean diet, 
should be encouraged.
 6 Increased physical activity must be encouraged to pre-
vent hypertension and obesity.
 7 Support population level programs to reduce sugar 
consumption, increase physical activity, and promote 
healthy diets to prevent and treat obesity  [437] . 
 Recommendation 12: On Follow-Up of LBW, SGA, 
and Preterm Infants, and Those Who Were Born 
in Pregnancies Complicated by Hypertension, 
Preeclampsia, or Gestational Diabetes 
 • Rationale 
 A recent systematic review (31 studies) showed a 
70% risk increase in CKD in adulthood for LBW indi-
viduals or those who experienced IUGR, with combined 
OR of 1.81 (95% CI, 1.19–2.77) for albuminuria, 1.58 
(95% CI, 1.33–1.88) for ESKD, and 1.79 (95% CI, 1.31–
2.45) for low GFR  [16] . Others have reported reduced 
GFR and greater albuminuria in individuals born pre-
term from childhood to young adulthood  [31, 438] . 
Similarly, 2 meta-analyses found a significantly in-
creased risk of higher blood pressures among those 
born <2.5 kg versus  ≥ 2.5 kg (odds of hypertension 1.21; 
95% CI, 1.13–1.30) or preterm or VLBW (pooled differ-
ence 2.55 mm Hg; 95% CI, 1.7–3.3 mm Hg) compared 
to term individuals  [21, 22] . The mean increase in sys-
tolic blood pressure at age 9 years among offspring of 
pregnancies complicated by gestational hypertension 
was 2.04 mm Hg (95% CI, 1.42–2.67 mm Hg) and by 
preeclampsia was 2.05 mm Hg (95% CI, 0.72–3.38 mm 
Hg)  [356] . Interestingly, the difference was attenuated 
after controlling for gestational age and birth weight in 
offspring who experienced preeclampsia but not gesta-
tional hypertension, suggesting possible diverse pro-
gramming mechanisms. In addition, in women born 
preterm before 32 weeks of gestation, pregnancies have 
an increased risk of GDM (OR 2.34; 95% CI, 1.65–3.33), 
gestational hypertension (OR 1.56; 95% CI, 1.09–2.25), 
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or preeclampsia/eclampsia (OR 1.79; 95% CI, 1.19–
2.69)  [124] . These odds were lower but still increased 
among those born between 32 and 36 gestational weeks. 
LBW and preterm birth should be recognized as risk 
factors (not causes) for hypertension, diabetes, CVD, 
and renal disease later in life, and as a risk factor for 
pregnancy-associated complications  [21–23, 211, 262] . 
The risk of these conditions is augmented in the setting 
of overweight/obesity  [439, 440] .
 Since there are no evidence-based guidelines for the 
follow up of individuals who had been LBW, SGA, pre-
term, or born in preeclamptic or diabetic pregnancies, we 
suggest the following recommendations, which may re-
quire local adaptation dependent on prevailing resources 
and practices.
 • Recommendations for action 
 1 Health care workers should clearly communicate the 
need for follow-up in at-risk infants to parents and col-
leagues to ensure appropriate follow-up occurs.
 2 Growth-restricted, preterm, or LBW infants as well as 
those exposed to preeclampsia or GDM should under-
go annual blood pressure measurement at least from 3 
years of age, as recommended by the American and 
European guidelines, and annual urinalysis  [441, 442] .
 3 Very premature children (<32 weeks of gestation) or 
children with VLBW or AKI postnatally should be 
screened initially at not later than 1 year of age  [88] .
 4 To detect small kidneys, asymmetry, or structural ab-
normalities, we suggest, if feasible, a baseline renal ul-
trasound, and follow-up should be performed as indi-
cated  [89] .
 5 If high blood pressure, previous AKI, proteinuria, as-
sociated CVD, renal anomalies, obesity, or diabetes are 
present, assessment of renal function, including also 
albuminuria and proteinuria, should be performed at 
least every 2 years until school entry  [136] .
 6 Screening of children who were growth restricted, pre-
term, LBW, or exposed to preeclampsia or GDM 
should be performed at planned checks of child health 
 status,  medical visits, or at 2-year intervals throughout 
school years.
 7 In low-resource settings, such intense follow-up may 
not be possible; however, simplified screening could 
coincide with public health interventions such as vac-
cinations or mass drug administration campaigns or 
conducted by community health workers.
 8 Under all circumstances, it is important that preterm 
or LBW children are not labeled “sick”, and, therefore, 
screening should be integrated with other health ac-
tivities if possible.
 9 Any abnormalities in kidney function or ultrasound 
should be followed up, with prompt referral, where 
possible, to a pediatrician or pediatric nephrologist.
 10 Families of preterm or LBW children should be in-
structed about a healthy lifestyle and avoidance of 
nephrotoxic agents.
 11 Rapid weight gain in infancy and early childhood 
should be avoided to reduce exacerbation of renal risk 
associated with obesity.
 12 From childhood onwards, a careful dietary habit 
with low salt and reduced carbohydrates and satu-
rated fat, as well as adequate physical activity should 
be adopted.
 13 From age 18 years onwards, we recommend monitor-
ing of blood pressure, BMI, and urinalysis 2 yearly un-
til 40 years of age, and thereafter at yearly intervals.
 14 Individuals with high blood pressure or abnormal pro-
teinuria require long-term follow-up and timely insti-
tution of renoprotective therapy.
 15 From 30 years of age, fasting blood glucose should be 
monitored in subjects with high BMI.
 16 For pregnant women born preterm or with LBW, close 
monitoring for gestational weight gain, fetal growth, 
and preeclampsia is suggested.
 17 Healthy lifestyle choices should be promoted through-
out life.
 18 Smoking should be avoided.
 Recommendation 13: On Regular Monitoring of 
Mothers of LBW and Preterm Infants, and Those Who 
Experience Preeclampsia or GDM 
 • Rationale 
 Mothers of infants born SGA, of LBW, or preterm, or 
who experienced preeclampsia are at an increased risk 
of renal and CVD later in life  [371, 443, 444] . Mothers 
who experience preeclampsia are at increased risk of re-
nal disease, CVD, and ESKD in later life  [58, 62] . Moth-
ers experiencing GDM are at increased risk of develop-
ing overt diabetes over time ( Table 11 )  [372, 445] . Al-
though these long-term risks are well recognized, uptake 
of subsequent maternal screening is poor, even when of-
fered free of charge  [445] . New mothers must be edu-
cated about the need for follow-up immediately post-
partum and at follow-up visits for the child, and health 
care workers must be aware of the risk and need for fol-
low-up.
 • Recommendations for action 
 1 The occurrence of GDM or preeclampsia must be 
prominently documented in a woman’s medical re-
cord and communicated to health care providers.
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 2 Mothers should be followed up 3 monthly until blood 
pressure, proteinuria, and blood sugars normalize 
postpartum.
 3 Mothers in whom these parameters do not normalize 
should be treated and followed appropriately.
 4 The effectiveness of combined mother/baby clinics in 
improving rates of maternal follow-up within the first 
5 years postpartum should be studied and if successful 
scaled up and rolled out.
 5 At each follow-up visit, mothers should receive healthy 
lifestyle education and education about preventing 
risk of disease in themselves and their children.
 6 Mothers should be screened lifelong for overweight/
obesity, blood pressure, diabetes, hyperlipidemia, 
CVD, and renal diseases every 1–3 years as age-appro-
priate guidelines suggest and treated appropriately.
 Recommendation 14: On Potential Living Kidney 
Donors Who Had Been Preterm, SGA, or LBW and 
Mothers Who Had Preeclampsia 
 • Rationale 
 Recent studies have suggested that living donation 
may not be as innocuous as once thought, making it im-
perative to better understand predictors of renal func-
tional decline in living donors  [193, 200, 446, 447] . Fol-
low-up of living kidney donors for up to 5 years showed 
that GFR was lower, proteinuria was higher, and new-
onset hypertension was more common in donors with 
lower birth weights  [203] . The effects were more evident 
in donors aged over 50, suggesting that LBW, nephron 
loss, and age compound renal function worsening over 
time. Transplant donors for groups that are at higher risk 
of renal disease and LBW or HBW (African-Americans, 
Australian Aboriginals, and Aboriginal Canadians), all 
appear to have higher risks of proteinuria and renal dys-
function over time, meaning that potential donors from 
these groups must be thoroughly evaluated and followed 
up ( Table 8 ). In addition, a recent study found an 86% 
increased risk of ESKD among obese compared to non-
obese living kidney donors over 20 years  [448] .
 Although, to our knowledge, no studies have explicitly 
examined the question, women who have experienced 
preeclampsia are themselves at increased risk of develop-
ing ESKD compared to those who did not experience pre-
eclampsia (RR 4.7; 95% CI, 3.6–6.1 in a Norwegian regis-
try study)  [204] . Although the absolute risk remained 
small, the RR increased in women who experienced pre-
eclampsia in more than 1 pregnancy ( Table 11 ). It is pos-
sible that this risk may increase or accelerate after the do-
nation of 1 kidney. In addition, women who donate a
kidney are at increased risk of gestational hypertension 
and preeclampsia compared to nondonors (OR 2.4; 95% 
CI, 1.2–5.0)  [449] . A cautious donor history in women 
must include obstetrical history.
 • Recommendations for action 
 1 Caution should be exercised in screening potential 
kidney donors who were born growth restricted, LBW, 
or preterm, or who were offspring of diabetic pregnan-
cies and LGA.
 2 Questions about birth weight and birth circumstances, 
as well as prior history of preeclampsia or GDM, 
should be routine for all potential donors.
 3 Renal function should be tested rigorously before do-
nation is considered.
 4 Any potential donor who was born SGA, LBW, pre-
term, or LGA should not be accepted for donation if 
there is any degree of proteinuria, elevation in blood 
pressure, diabetes, or BMI >25 given the fundamental 
obligation to “do no harm.”
 5 Any donor who was born SGA, LBW, or preterm, or 
who experienced preeclampsia, should be monitored 
closely for the rest of their lives after donation, ideally 
by a nephrologist, and they should be strongly encour-
aged to avoid overweight/obesity, and to have hyper-
tension and diabetes treated early.
 6 Potential donors who had GDM, even if currently nor-
moglycemic, must be counseled extensively about the 
risk of developing subsequent diabetes, the exacerba-
tion of this risk with weight gain, and the risk of accel-
erated loss of renal function in a single kidney should 
overt diabetes develop. Such donors require long-term 
follow-up.
 Global Health Implications of Renal Developmental 
Programming and Call to Action 
 Hypertension and CKD have a significant impact on 
global morbidity and mortality  [9, 450] . LBW, prematu-
rity, SGA, HBW, childhood obesity, maternal obesity, 
GDM, and preeclampsia are all highly prevalent across 
the globe. The proportion of the chronic disease burden 
contributed by developmental programming is difficult 
to quantify, but it is likely to be significant due to the high 
prevalence of programming risk factors in both high- and 
lower-income countries. Preventing risk factors for 
IUGR, LBW, and prematurity, and optimizing maternal 
health are likely to be the most comprehensive strategies 
to reduce this burden as outlined in the Minsk Declara-
tion and the WHO publication on “Good Maternal Nu-
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trition. The Best Start in Life”  [1, 3] . Improving all health-
related and structural factors that impact maternal health 
prior to conception, during pregnancy, and child nutri-
tion, as well as development after birth, requires a multi-
sectoral approach extending beyond the health system, 
encompassing governance and health policy, the alloca-
tion of appropriate funds for health care, education, in-
frastructure, medical technologies, access to medication, 
and appropriately trained health care professionals, reli-
able data capture and monitoring, and ongoing research 
to develop effective implementation strategies. Increased 
awareness of the risks of developmental programming is 
imperative. Infants should be weighed at birth, gestation-
al age determined, and these facts documented. Neona-
tologists should be aware of the risk of AKI and the im-
portance of documenting this in discharge communica-
tions, and they should try to minimize the exposure of 
preterm and SGA infants to nephrotoxins. Families 
should be educated about healthy lifestyle strategies to 
minimize obesity and malnutrition. Children should be 
monitored for hypertension or proteinuria, especially if 
they experience rapid catch-up growth. Mothers with 
LBW or preterm children, or those who had preeclamptic 
pregnancies or GDM, require long-term follow-up for 
cardiovascular risk factors and disease management, as 
well as close monitoring in future pregnancies. Potential 
kidney donors should be asked about their birth history 
and birth weight, and careful consideration should be giv-
en to potential risks in individual donors.
 Understanding the potential long-term benefits of 
such interventions is crucial to inform policy decisions to 
interrupt the developmental programming cycle and 
stem the growing epidemics of hypertension and kidney 
disease worldwide.
 Conclusions 
 The recommendations for action of our consensus 
workshop are the results of combined clinical experience, 
shared research expertise, and a review of the literature 
made by obstetricians, neonatologists, and nephrologists 
of the Low Birth Weight and Nephron Number Working 
Group (see Appendix).
 They highlight the need to act early to prevent CKD 
and other related NCD later in life by reducing LBW, 
SGA, prematurity, and low nephron numbers at birth 
through coordinated intervention by obstetricians, neo-
natologists, nephrologists, and family physicians  [15, 
451] . This is particularly relevant for resource-poor coun-
tries that experience the burdens of maternal, fetal, and 
childhood undernutrition and poor health, which syner-
gistically act to augment the effect of developmental pro-
gramming of chronic diseases, which also disproportion-
ally affects low- and middle-income regions. Thus, devel-
oping countries are the most vulnerable to the effects of 
the developmental programming life cycle. Our recom-
mendations are consistent with and complement the 
Global Goals for Sustainable Development proposed by 
the United Nations  [4] , where ending poverty and hun-
ger, enhancing food security, decreasing teenage preg-
nancy, empowering and educating girls and women, re-
ducing maternal infections, and managing chronic dis-
eases may reduce the risk of LBW, SGA, preterm birth, 
preeclampsia, GDM, and maternal and childhood obesi-
ty, and, therefore, hold the promise of a positive impact 
on the renal health of future generations.
 The working group has also indicated that there are 
many remaining gaps that require further research stud-
ies in the field, including but not limited to the establish-
ment of registries for documenting LBW, prematurity, 
and infants born SGA (especially in resource-poor re-
gions), conducting intervention trials, and identifying 
new early biomarkers of risk [interesting readers may re-
fer to the full list of suggestions for further research stud-
ies mentioned in  15, 451 ].
 Meeting these unmet needs would help to define the 
most cost-effective strategies and to optimize interven-
tions to limit or interrupt the developmental program-
ming cycle of major NCD, including CKD later in life, 
especially in the poorest parts of the world.
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